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SUMMARY
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. 
Current knowledge suggests that MS is associated with autoimmunity and that infectious 
agents and hereditary factors may be involved. The demonstration of a higher 
recurrence risk of MS in families (4-5%) compared with the general population (0.1%) 
provides strong evidence for a genetic basis. Extensive analyses of the entire human 
genome to identify new genes that may underlie MS have indicated that several genes 
may contribute to disease susceptibility, but these remain largely unidentified.
In this study candidate genes involved in iron metabolism and immunology have been 
analysed for the first time within the context of both autoimmune and infectious disease 
susceptibility, in order to investigate the role of genetic and viral factors implicated in the 
pathogenesis of MS.
The Z-DNA forming repeat polymorphism in the promoter region of the solute carrier 
family 11 (proton-coupled divalent ion transporters) member 1 (SLC11A1) gene was 
found to be significantly associated with MS (P<0.01) in the genetically homogeneous 
Afrikaner population of South Africa, but not in the German and French populations 
using a case-control study and transmission linkage disequilibrium approach, 
respectively. However, significant differences were observed in genotype distribution 
between German MS patients with a primary- and secondary progressive disease 
course (P<0.05), and between the German patients with relapsing remitting and primary 
progressive MS (P<0.05). These findings provide further evidence that the SLC11A1 
gene is associated with MS, most likely due to its role in iron homeostasis.
In order to investigate the influence of viruses in the apparent multi-step aetiology of MS, 
serum and peripheral blood mononuclear cells (PBMCs) of MS patients, close relatives 
and unrelated controls were screened for the presence of MS-associated retrovirus 
(MSRV) and two herpes virus (HHV-6 and EBV) sequences. Detection of the pol gene 
expression of MSRV in the serum RNA of 69% of South African MS patients and in 70%
Stellenbosch University http://scholar.sun.ac.za/
of their unaffected close relatives, whilst absent in the serum of 39 unrelated healthy 
control individuals (P<0.001), indicated that virus infections affect the population risk but 
not the familial risk in MS. HHV-6 sequences were also present at a significantly lower 
frequency (P<0.04) in the PBMCs of unrelated controls (5%) compared to MS patients 
(22.5%).
A point mutation (77C ^G ) in the gene encoding protein-tyrosine phosphatase, receptor- 
type C (PTPRC), which is essential for activation of T and B cells, was found to be 
associated with MS in the German population. Analysis of the Afrikaner and German 
study populations included in our study did not indicate a causative role for the PTPRC 
gene in MS. However, it seems likely that this mutation may contribute to disease 
expression, since in one of the South African families with two MS affected sibs, the 
most severely affected sister was heterozygous for the 77C-»G mutation. The PTPRC 
mutation may therefore be of significance in disease prognosis.
The multidisciplinary study approach has led to a stepwise accumulation of scientific 
information, which forever changed our understanding of the disease process underlying 
MS.
Stellenbosch University http://scholar.sun.ac.za/
OPSOMMING
Veelvoudige sklerose (VS) is ‘n kroniese inflammatoriese siekte van die sentrale 
senuweestelsel. Oor die algemeen word aanvaar dat VS geassosieerd is met 
outoimmuniteit en dat infektiewe agente en oorerflike faktore ’n rol speel. Die hoer 
herhalingsrisiko van VS in families (4-5%) in vergelyking met die voorkoms in die 
algemene populasie (0.1%) dui op 'n genetiese basis. Alhoewel volledige analise van 
die mensgenoom om gene onderliggend aan VS te identifiseer aangedui het dat 
verskeie gene waarskynlik bydra tot vatbaarheid vir die siekte, is die aard van die gene 
wat betrokke is grootliks onbekend.
In hierdie studie is kandidaatgene betrokke by ystermetabolisme en immunulogie vir die 
eerste keer geanaliseer binne die konteks van beide outoimmuun en infektiewe siekte 
vatbaarheid, ten einde die rol van genetiese en virale faktore in die patogenese van VS 
te ondersoek.
Die Z-DNS herhalingsvolgorde polimorfisme in die promotor area van die SLC11A1 
geen was betekenisvol geassosieerd met VS (P<0.01) in die geneties homogene 
Afrikaner populasie van Suid-Afrika. ’n Soortgelyke assosiasie kon egter nie aangetoon 
word in die Duitse en Franse populasies deur gebruik te maak van onderskeidelik ‘n 
gevalle-kontrole studie en transmissie-koppelings-disekwilibrium benadering nie. 
Betekenisvolle verskille in die genotipe verspreiding is egter tussen Duitse VS pasiente 
met ‘n sekonder- en primer progressiewe verloop van die siekte (P<0.05), en tussen die 
Duitse pasiente met terugvallende en primere progressiewe VS aangetoon (P<0.05). 
Hierdie bevinding verskaf verdere bewyse dat die SLC11A1 geen geassosieerd is met 
VS, heel waarskynlik weens die rol van die geen in yster-homeostase.
Ten einde die invloed van virusse in die etiologie van VS te ondersoek is serum en 
witbloedselle van VS pasiente, naby-verwante familielede en nie-verwante kontroles 
getoets vir die teenwoordigheid van die VS-geassosieerde retrovirus (MSRV) en twee 
herpesvirus (HHV-6 en EBV) geenvolgordes. Die pol geen uitdrukking van MSRV was
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teenwoordig in die serum RNA van 69% van die Suid-Afrikaanse VS pasiente en in 70% 
van hul ongeaffekteerde naby-verwante familielede, terwyl dit afwesig was in 39 nie- 
verwante kontrole individue (P<0.001). Dit dui daarop dat virusse waarskynlik die risiko 
vir VS meer in die populasie verhoog as in families. HHV-6 was ook teenwoordig teen ‘n 
beduidende laer frekwensie (P<0.04) in nie-verwante kontroles (5%) in vergeleke met 
VS pasiente.
‘n Puntmutasie (77C-G) in die geen wat kodeer vir die proteien tirosien fosfatase 
reseptor tipe C (PTPRC), wat belangrik is vir aktivering van T- en B-helperselle, is 
vroeer gevind om geassosieerd te wees met VS in die Duitse populasie. Analise van die 
Afrikaner en Duitse populasies in ons studie het egter geen bewyse gelewer dat die 
PTPRC geen ‘n rol speel in VS nie. Dit egter is moontlik dat hierdie mutasie bydra tot die 
uitdrukking van VS, aangesien die mees geaffekteerde VS pasient in een van die Suid- 
Afrikaanse families met twee geaffekteerde susters positief getoets het vir die mutasie. 
Die mutasie mag dus van belang wees in die prognose van VS.
Die multidissiplinere studie-benadering en stapsgewyse insameling van wetenskaplike 
inligting het gelei tot ’n nuwe perspektief ten opsigte van die siekteproses onderliggend 
aan VS.
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HLA human leukocyte antigen
HLA-A3 human leukocyte antigen A3
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HSV human simplex virus
HTVL-1 human T-lymphotropic virus type 1
IFN interferon
ig immunoglobulin
igG immunoglobulin G
IgAD IgA deficiency
IL interleukin
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LOD logarithm of odds
M molar, moles per litre
MCP-3 monocyte chemotactic protein 3
MDV marek’s disease virus
MHC major histocompatibility complex
M9/I microgram per litre
Ml microlitre
pmol/l micro mole per litre
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mM milli molar
MRI magnetic resonance imaging
MS multiple sclerosis
Mse 1 restriction endonuclease enzyme
Msp 1 restriction endonuclease enzyme
MSRV multiple sclerosis-associated retrovirus
ng nanogram
n.d. not determined
NPL nonparametric linkage
NRAMP1 natural resistance-associated macrophage protein 1
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OCB oligoclonal band
%C percent crosslink
PAA polyacrylamide
PBMC peripheral blood mononuclear cell
PCR polymerase chain reaction
PGE2 prostaglandin E
pmol pico mole
PP primary progressive
PPOX protoporphyrin oxidase
PTPRC protein-tyrosine phosphatase, receptor-type C
RNA ribonucleic acid
RNAse modifying enzyme, ribonuclease
RR relapse remitting
Rsa 1 restriction endonuclease enzyme
RT-PCR reverse transcriptase PCR
SLC11A1 solute carrier family 11 member 1
SP secondary progressive
TDT transmission/disequilibrium test
TNF tumor necrosis factor alpha or alpha and beta
U units
yrs age in years
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1CHAPTER 1 
INTRODUCTION
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2INTRODUCTION
MULTIPLE SCLEROSIS: A DISEASE OF THOUSAND FACES
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) 
characterised by multifocal damage of myelin and axonal loss resulting in various 
neurological symptoms. This disease does not follow a predictable pattern of inheritance 
and cannot yet be explained through an effect of a definable gene product or functional 
abnormalities (Chataway et al., 1998). The geographic heterogeneity of the disease and 
the varying prevalence rates in different population and ethnic groups suggest interplay 
between environmental and genetic factors. This calls for a multi-disciplinary approach 
to elucidate the aetiology of MS.
1.1 Clinical presentation, diagnosis, pathology and treatment
1.1.1 Clinical features
A wide range of clinical symptoms and signs, few of which are considered particularly 
specific to the disease, are exhibited by MS. Strikingly uniform however is the long-term 
outcome in disease severity (Ebers, 2000). Depending on the part of the CNS affected, 
the signs and symptoms of the patients vary. Some tend to appear early in the course of 
the disease and some later. Sensory impairment was the most common symptom in the 
initial stages, followed by optic neuritis, insidious motor functional impairment, limb 
ataxia, diplopia and/or vertigo and acute motor functional loss (Weinshenker et al., 
1989). Abnormal reflexes, impairment of bowel and bladder control and sexual 
dysfunction are other observed signs. MS patients are more frequently affected by 
memory impairment and affective disorders as compared to the general populations 
(Miller, 1998).
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31.1.2 Clinical categories and severity classification
MS may be categorised into several different types according to clinical course. There 
was clear consensus and preferences on the meaning of the terms relapsing remitting 
(RR), primary progressive (PP) and secondary progressive (SP) forms of MS as 
revealed by an international survey of clinicians involved with MS. According to the 
authors (Lublin and Reinhold, 1996) it was suggested that the PR form deserves a 
separate definition, as it was not included in the other definitions. As PR represents only 
a small fraction of MS patients, this suggestion has received very little support. The 
consensus definitions are as follows:
RR: Clearly defined disease relapses with full recovery or with sequelae and residua 
deficit upon recovery. Periods between disease relapses characterised by a lack o 
disease progression.
SP: Initial RR disease course followed by progression with or without occasional 
relapses. Minor remissions and plateaus may be accepted.
PP: Insidious onset and disease progression from onset with occasional plateaus an< 
temporary minor improvements allowed.
PR: Progressive disease from onset, with clear acute relapses, with or without full 
recovery; periods between relapses characterised by continuing progression.
An increasing disability is displayed by PP and SP patients. A disability status scale, « 
scoring system for disability, was developed by Kurtzke (1983) and was later expands 
to include more subtle changes. The expanded disability status scale (EDSS) is used ti 
measure MS-related impairment of various functional systems. These are pyramida 
cerebellar, brain-stem, sensory, bowel/ bladder, visual and cerebral functions as well a 
other neurological findings attributable to MS. Impairment is graded in 20 steps startin< 
from zero (normal neurological examination) increasing to 1 (a single sign only) and thei 
in half-point steps ranging to 10 (demise by MS). A median time of 15 years to EDSS 6 
20 years for EDSS 7 and 25 years for EDSS 8 in RR MS was indicated by Ebers (2000; 
In the PP MS group it was 8 years to EDSS 6, 12 years to EDSS 7 and 15 years t  
EDSS 8. Definitions of benign and malignant MS, concerning severity of disability, hav
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4also been suggested (Lublin and Reinhold, 1996). If a sufferer remains fully functional in 
all neurologic systems after 15 years of disease onset, it is diagnosed as benign MS. A 
speedy progressive course, leading to significant disability in multiple neurologic 
systems or death in a relative short time after onset of disease, is categorized as 
malignant MS. Benign MS is normally considered a sub-category of RR MS. RR MS 
attacks are more frequent and some patients have a stepwise increase in neurological 
deficit as compared with benign MS.
1.1.3 Disease subtypes
Immunogenetic studies of human leukocyte antigen (HLA) have indicated that there may 
be two distinct sub-types of MS: Asian-type and Western-type. The clinical differences 
between Western and Asian types of MS based on the natural history of the disease as 
well as magnetic resonance imaging scanning of the brain and spinal cord of a group of 
Japanese patients, was reported by Kira et al. (1996). The patients, all residing in 
Kyushu, were diagnosed as having a Western or Asian type MS. Asian type MS was 
characterized by a RR course and a selective involvement of the optic nerve and spinal 
cord. This disease pattern is known to occur in some Asian populations. Disseminated 
central nervous system (CNS) disease was more prevalent in patients with Western type 
MS. Western type MS sufferers showed a DR2 association, which Asian type MS 
patients did not. This led to Kira at al. (1996) to suggest the presence of two 
aetiologically distinct diseases in Asians. A study done by Dean et al. (1994) indicated 
that MS in the black South African populace, albeit rare, has more similarities with the 
disease as occurring among the oriental people, than among the white people in 
Southern Africa or black people of North America or the Caribbean.
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51.1.4 Pathology
The oligodendrocyte, a principal target of immune attack in MS patients, synthesises 
and maintains the myelin sheath of up to 40 neighbouring nerve axons in the CNS. 
Myelin consists of a condensed membrane, spiraled around axons to form the insulating 
segmented sheath needed for salutatory axonal conduction. A cluster of voltage-gated 
sodium channels can be found at the unmyelinated nodes of Ranvier between the 
myelin segments from where the action potential is propagated and spreads passively 
down the myelinated nerve segment to trigger another action potential at the next node. 
The clinical and biochemical features associated with MS can thus be explained by the 
consequences of demyelination. For example, partially demyelinated axons conduct 
impulses at reduced velocity, explaining the characteristic delays in conduction of 
evoked potentials. Demyelinated axons can discharge spontaneously and show 
increased mechanical sensitivity, accounting for the flashes of light on eye movement 
and electrical sensation running down the spine or limbs on neck flexion (Lhermitte’s 
symptom and sign). Partially demyelinated axons whose conduction is compromised 
cannot sustain the fall in the membrane capacity due to a rise in temperature leading to 
the appearance of symptoms after a hot bath or exercise (Uhthoffs phenomenon).
1.1.5 MS diagnostic criteria
There is no definitive diagnostic test for MS, but the emerging modern paraclinical 
techniques such as magnetic resonance imaging (MRI), oligoclonal bands (OCB) and 
evoked potentials (EPs) can facilitate diagnosis. The diagnosis of MS is fundamentally 
clinical and requires that a patient at the appropriate age had two distinct episodes of 
neurological disturbances implicating distinct sites in the white matter of the CNS. Other 
possible causes for the clinical symptoms need to be excluded before a diagnosis of MS 
can be made (Compston, 1998). The diagnostic criteria as suggested by Poser et al. 
(1983) form the basis of the diagnostic procedure, although an international panel on 
MS diagnosis recently presented revised diagnostic criteria (McDonald et al., 2001). 
These authors defined attacks as symptoms of neurological dysfunction, with or without 
objective confirmation, lasting for more than 24 hours. Clinical evidence of lesions
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6indicates signs of neurological dysfunction demonstrable by neurological examination. 
Paraclinical or subclinical evidence indicates lesions that are only demonstrable by 
various tests, such as MRI and EPs, and not by clinical neurological examination, 
laboratory support applies only to examination of cerebral spinal fluid (CSF) for 
oligoclonal bands and increased production of immunoglobulin G (IgG).
The Poser criteria have been most commonly used for the identification of patients to be 
included in epidemiology studies or therapeutic trails in recent years. In the revised 
criteria, the focus remains on the objective demonstration of dissemination of lesions in 
both time and space. These new MS criteria accept the diagnosis of patients with a 
variety of presentations, including monosymptomatic disease suggestive of MS, disease 
with a typical RR course and disease with insidious progression, without clear attacks 
and remissions. This reflects an improved understanding of the disease and usefulness 
of new technology.
1.1.6 Treatment
Since different immunopathological pathways appear to be involved in different 
subgroups of MS patients, the treatment of this disease may be more complex than 
previously anticipated (Lassmann, 1999). Available treatments for (relapsing forms of) 
MS are only partially effective, and therefore steps need to be taken to identify more 
effective treatments for this disease (Noseworthy, 1999). Future treatment options 
include strategies to interfere with disease-relevant, specific or nonspecific immune 
mechanisms and drugs that might promote remyelination (van Oosten et al., 1998). In a 
recent study the potential benefits of antioxidant administration together with an 
appropriate diet has also been highlighted (Syburra and Passi, 1999). Choosing specific 
treatment for a given patient and using specific drugs in different disease stages could 
potentially improve the outcome. Genetic determination is hypothesised to be 
responsible for diverse therapeutic responses. Thus, identification of genetic 
polymorphisms influencing drug metabolism may significantly facilitate the development 
of effective therapies. Compston and Coles (2002) discussed at length the five aims of 
treatment, namely:
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71. reduce relapse rates
2. prevent fixed disability linked to relapse
3. provide symptomatic management of fixed neurological deficits
4. prevent disability acquired through progression
5. treat established progression
Current treatments involve either steroids, which fight inflammation caused by the 
immune system reaction, or immuno-suppressant drugs, which depress immune system 
function. Both these approaches create serious side effects and may slow, but not stop, 
the progress of the disease. They are also effective mostly at very early stages of 
disease.
1.2 Natural history of Multiple Sclerosis
1.2.1 Prevalence and disease onset
MS affects approximately 2,5 million people across the globe (Homes et al., 1995). 
Although more females are affected (2:1), there is no difference in disease severity 
between the sexes. This disease has an incidence of about 7 per 100 000 every year, a 
prevalence of about 120 per 100 000 and a lifetime risk of 1 in 400. Disease onset is 
usually in the third or fourth decade, but 2% of patients with MS present before the age 
of 10 years and 5% before the age of 16 years. Eighty percent of patients present with 
RR MS, and in a quarter of these patients, MS never affects daily activities, while up to 
15% become severely disabled within a short period of time. In the remaining 20% the 
disease is progressive, affecting the spinal cord and less frequently the optic nerve, 
cerebrum or cerebellum. Life expectancy is at least 25 years from disease onset and 
most patient’s die from unrelated causes (Compston and Coles, 2002).
1.2.2 Geographic Distribution
In a recent report on the worldwide prevalence of MS (Pugliatti et al., 2002) the difficulty 
in defining the geographical distribution of MS (figure 1) was pointed out. Prevalence 
studies from different areas assessed at different times had to be compared and the 
problems encountered were as follows:
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81. Variability of surveyed population (size, age structure and ethnic origin and 
composition) (Rosati, 1994).
2. Difference when determining the numerator (early cases or benign MS) 
(Sadovnick and Ebers, 1993)
3. Ascertainment of cases i.e. geographic and time variables, access to medical 
care, local medical expertise, number of neurologists and accessibility to new 
diagnostic procedures (Sadovnick and Ebers, 1993; Noseworthy et al., 2000).
4. Use of different diagnostic criteria and the interobserver variability in application.
Taking all this into account it is better to describe the global prevalence of MS in three 
frequency zones (Kurtzke, 2000):
• High frequency areas (more than 30 cases per 100 000) include Europe, 
Israel, Canada, northern US, southeastern Australia, New Zealand, and 
easternmost Russia.
• Medium frequency areas include southern US, rest of Australia, South 
Africa, the southern Mediterranean basin, Russia into Siberia, the Ukraine 
and parts of Latin America.
• Low frequency areas (less than 5 cases per 100 000) include the rest of 
Asia, Africa and northern South America.
The data from migration studies suggest that if the exposure to a higher risk 
environment occurs during adolescence (before 15 years of age), then the migrant 
assumes the higher risk of the environment. This concept was illustrated in studies of 
the native-born South African white population with low incidence of the disease versus 
high incidence of MS among white immigrants from Great Britain, where the disease is 
much more prevalent (Dean and Elian, 1993).
"Epidemics" of MS have been reported and these provide further evidence of the 
importance of environmental factors in MS. The most notable "epidemic" was described 
on the Faroe Islands after they were occupied by British troops in World War II. Similar
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9increases in incidence of the disease were seen on Shetland and Orkney Islands, in 
Iceland, and in Sardinia. A specific "point agent" for these "epidemics" was never 
identified (Kurtzke, 2000).
Figure 1: World distribution of multiple sclerosis (adapted from Kurtzke, 2000).
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There are also population studies that show difference in susceptibility to MS between 
different populations. Lapps in Scandinavia appear to be resistant to the disease, 
contrary to the expectations based on their geographic distribution. Native Americans 
and Hutterites very infrequently suffer from MS, as opposed to other residents of North 
America. MS is uncommon in Japan, China and South America. It is practically unknown 
among the indigenous people of equatorial Africa and among native Inuit in Alaska. 
When the racial differences are correlated, White populations are at greater risk than 
Asian or African populations. We cannot yet explain these obvious inconsistencies in 
disease distribution, but the knowledge of them may be helpful in assessing specific 
patients (Weinshenker et al., 1989).
1.3 Aetiology
1.3.1 Autoimmunity
The autoimmune nature of MS has long been suspected. It is known that patients with 
MS have inflammation and demyelination in their CNS and oligoclonal bands in their 
cerebrospinal fluid (CSF). These abnormal immunoglobulins are identified in a high 
percentage of patients with clinically definite MS during exacerbations of RR disease, or 
persistently in a significant proportion of chronic-progressive patients. The composition 
of the inflammatory infiltrate together with the local expression of various cytokines and 
other immune-associated molecules suggest that the basis of the inflammatory 
response is a T-cell mediated immunological process (Cannella and Raine, 1995; 
Sorensen et al., 1999; Lassmann, 2002). The T-cell mediated inflammation leads to 
proliferation, activation, and entry into the circulation of autoreactive T cells; they 
express adhesion molecules and induce reciprocal change in endothelia, allowing 
access across the blood-brain barrier into the CNS mediating damage associated with 
the disease (Compston and Coles, 2002). In MS immune dysfunction can be detected 
locally in CNS and CSF as well as systemically in peripheral circulation (table 1).
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Table 1: Immunologic abnormalities in CSF, whole blood and serum in MS patients.
CSF Serum Blood
A IFN-gamma A IFN-gamma A IFN-gamma
A IgG and oligoclonal 
bands
A TNF A IL-2
A TNF A IL-2 A IL-4
A activated CD4+ cells A IL-2 receptors A IL-1
T PGE-2 release by 
macrophages
T CD8+
IFN-gamma, interferon gamma; IgG, immunoglobin G; TNF, Tumor necrosis factor alpha or alpha and beta; CD4+, MHC class II 
restricted T-cells; CD8+, MHC class I restricted T-cells; IL-1,2,4, interleukins; PGE2, prostaglandin E
1.3.2 Viral factors
The clinical and pathological features of MS implicate viral infections as either cofactors 
in its aetiology or triggers of relapses, although no specific environmental factors have 
been identified. Special focus has befallen several herpes viruses because of their 
ability to cause latent infections that periodically reactivate very similar to the RR course 
of MS. Furthermore, most herpes viruses can be readily found within the CNS and 
several are known to induce demyelination, both in humans and in experimentally 
infected animals (Simmons, 2001; Stohlman and Hinton, 2001).
There is a considerable interest in a theory that exposure to a virus may lead to 
immunopathologic condition resulting in MS. One possible explanation for this is 
molecular mimicry between viral and CNS proteins so that antiviral response is 
mediated against myelin. Molecular mimicry is characterised by an immune response to 
an environmental agent that cross-reacts with a host antigen resulting in disease (Levin 
et al., 2002). Another possibility is that autoimmunity results from super antigenic 
stimulation of T-cells by viral or bacterial proteins. Super antigens may bind to specific T- 
cell receptor proteins, producing non-specific stimulation of a large number of T-cells. 
This may result in clonal expansion of T-cells reactive to myelin or oligodendrogliocyte 
antigens. Levin et al. (2002) showed a clear link between virus infection, autoimmunity 
and neurological disease in humans by studying patients with human T-lymphotropic
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virus type 1 (HTVL-1 )-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a 
disease that may be indistinguishable from MS.
Perron et al. (1997) described a novel retrovirus that was dubbed MS-associated 
retrovirus (MSRV). This virus was detected in patients with MS, but not in control 
individuals. Dolei and co-workers (2002) analysed the blood and CSF of Sardinian MS 
patients and detected the MSRV in 50% and in 40% of control CSF. In the blood 
samples the MSRV was detected in all the samples and in some patients with 
inflammatory neurologic disease, but rarely in healthy blood donors (Dolei et al., 2002). 
The author concluded that MSRV might represent a marker of neurologic disease of 
inflammatory origin. In a recent review Simmons (2001) summarised the role of herpes 
virusses in MS (table 2).
Table 2: Summary of the potential role played by herpes viruses in MS (adapted from 
Simmons, 2001).
Relapsing
remitting
epidemiology
Geographical 
distribution 
consistent with 
MS
Circumstantial
serological
support
Virus or viral 
nucleic acid in 
blood or brain 
during acute 
MS
Plaque- 
associated viral 
antigen or DNA 
sequences
Viruses known 
to be 
neurotropic
HSV VZV EBV HSV HHV-6 HSV-1 and -2
EBV MDV HHV-6 HHV-6 VZV 
HHV-6 and -8
HSV, herpes simplex virus; VZV, varicella zoster virus; EBV, Epstein-Barr virus; HHV, human herpesvirus; MDV, Marek’s disease 
virus
1.3.3 Genetic factors
The estimated familial occurrence in Caucasian MS populations is about 15%. The age- 
adjusted risk is higher for siblings (3%), parents (2%), and children (2%) than for 
second-and third-degree relatives (figure 2). Recurrence in monozygotic and dizygotic 
twins is 35% and 6% respectively, and is higher in children of conjugal pairs with MS 
(20%) than in the offspring with a single affected parent (2%) (Ebers et al., 1995; 
Sadovnick et al., 2000; Compston and Coles, 2002). Genetic epidemiology has strongly 
suggested the involvement of genetic determinants in MS and the following statements 
surmise the results of genetic epidemiology and molecular genetic studies to date 
(Sadovnick, 2002).
Stellenbosch University http://scholar.sun.ac.za/
13
a. MS results from an interaction of genetic and environmental factors
b. The familial aggregation of MS is due to the genetic material these individuals 
share with the index patient
c. MS appears to be oligogenic (more than one gene involved)
d. HLA does not appear to be a “deterministic” gene for MS
e. Genetic susceptibility factors may overlap, at least to some extent, between the 
general population and individuals with MS
Figure 2: Lifetime risk of multiple sclerosis (adapted from Compston and Coles, 2002).
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1.4 The search for genetic factors underlying MS
While a relatively large number of genes may underlie the MS phenotype, interactions 
between different genes could result in a dramatic increase in disease susceptibility 
(synergistic gene effects). The genes that have attracted most interest as possible 
susceptibility factors in MS can be divided into three main groups: genes affecting 
immune functions, myelin structural genes and genes implicated in genome wide 
screening studies. Most of the gene associations described in a specific population 
could not be confirmed in other populations, suggesting that the genetic susceptibility 
factors of MS may vary between different populations. The following approaches have 
been sought by researchers in an attempt to explain the complexity of MS.
1.4.1 Whole genome screens
There are two methods to map susceptibility loci, namely linkage and association 
studies. Linkage studies entail the search for markers that co-segregate with a disease 
in a family whereas association studies compare allele frequencies at certain markers 
between clinically affected individuals and unaffected controls to identify possible 
statistically significant differences. The principal requirements for genome screening in 
complex traits are a sizeable and well-validated clinical resource, a map of highly 
polymorphic markers covering the whole genome and the technology to complete the 
large number of genotypings required (Chataway et al., 1998). The discovery of short 
sequence repeats (Nakamura et al., 1987), CA repeats (Weber and May, 1989), 
fluorescent labelling, sizing (Diehl et al., 1990; Ziegle et al., 1992) and mapping within 
the human genome (Dib et al., 1996) enabled genome screening to develop. 
Commercial companies market extensive genome kits in combination with high 
throughput technology and high-powered software for analysis. Since 1994 when the 
first genome screen was attempted (Davies et al., 1994), several studies of complex 
diseases such as MS have been performed. Table 3 provides a summary and overlap 
comparison of four genome screens (Haines et al., 1996; Sawcer et al., 1996; Ebers et 
al., 1996; Kuokkanen et al., 1997), two meta-analysis studies of the data (The 
Transatlantic Multiple Sclerosis Genetics Cooperative 2001; Wise et al., 1999) and a
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new genome wide screen on a Nordic population (Akesson et al., 2002). In none of 
these studies a single locus with formal significant linkage could be identified, but a 
number of chromosomal regions of importance were highlighted. In a meta-analysis of 
these four genome screens, Wise and co-workers (1999) identified 5 regions with a P- 
value less than 0.05. A meta-analysis performed by three of the original genome screen 
studies (Haines et al., 1996; Sawcer et al., 1996; Ebers et al., 1996) revealed a total of 
eight regions that had non-parametric linkage (NPL) scores greater than 2.0. The 
authors pointed out that overall, their linkage results suggest that MS is likely to be 
multigenic in its genetic susceptibility (The Transatlantic Multiple Sclerosis Genetics 
Cooperative 2001). In a recent study Akesson et al. (2002) identified 17 regions that 
exceeded the 5% significance lod score threshold, although no genome wide 
significance were observed. Using a DNA pooling strategy, Sawcer et al. (2002) 
confirmed previous linkage candidate areas at positions 1 p, 6p, 17q and 19q and stated 
that their pooling genome protocol is currently used in 18 additional European studies in 
order to search for susceptibility genes shared between populations of common 
ancestry, as well as ethnically diverse populations.
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Table 3: Summary and overlap comparison of genome screen results in different 
populations.
American 
(Haines et 
al., 1996)
British
(Sawcer et 
al., 1996)
Canadian 
(Ebers et 
al., 1996)
Finnish
(Kuokkanen 
et al.,
(1997)
Meta­
analysis 
(Wise et al., 
1999)
Meta
analysis
(Transatlantic
cooperation
2001)
Nordic 
(Akesson 
et al., 
2002)
1 p36-p33 1p36-p33
2p23 2p23-p21 2p23-p21 2p
3p14-p13 3p14-p13 3p
3q22-q24 3q22-q24 3q 3q21.1
4q31-qter 4q31-qter
5q13-q23 5q12-q13 5q12-q13 5q
6p21 6p21 6p21 6p 6p 6p 6p21
6q27 6q22-q27 6q
7q11-q22 7q21-q22
17q22 17q 17q11; 17q22 17q25
18p11 18p11
19q 13 19q12-q13 19q13 19q
Adapted from (Dyment et al., 1997)
There have been several follow-up studies concerning genomic regions of interest 
(Broadley et al., 2001; Chataway et al., 1998; Chataway et al., 1999; Coraddu et al., 
2001; D'Alfonso et al., 1999; Dai et al., 2001; Larsen et al., 2000; Oturai et al., 1999; 
Sawcer et al., 2002; Vandenbroeck et al., 2002; Vitale et al., 2002; Xu et al., 1999). 
Although the findings in genome screens revealed potentially interesting chromosomal 
regions, it failed to detect one major gene. This supports the notion that MS is indeed a 
polygenic disease where many genes are involved, each having a minor effect.
1.4.2 Candidate gene studies
Since MS is thought to be an autoimmune disease mediated by autoreactive T cells 
directed against myelin antigens, various cytokines, chemokines and their receptors and 
autoantigens etc. are attractive candidates for MS susceptibility. Thus far, studies trying
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to identify disease-modifying effects in MS have identified four genes of probable 
importance: HLA class II, apoE, IL-1ra and IL-1J3, Kantarci et al. (2002) gives a very 
comprehensive summery of association studies performed of non-MHC candidate genes 
with disease severity in MS (Kantarci et al., 2002). Known genetic factors considered to 
be of importance in MS susceptibility following a literature survey are discussed in the 
following sections.
1.4.2.1 HLA
Jersild and co-workers have reported in 1972 that MS is associated with HLA-A3, -B7 
and -Dw2. Since 1972, advances in HLA typing techniques, from cellular typing to 
serology and DNA full identification of HLA polymorphism, have shown that cellularly 
defined specificity Dw2, which has a confirmed role in MS, corresponds to DR15 and 
DQ6 in serologic nomenclature and to the haplotype DRB1*1501, DRB5*0101, 
DQA1*0102, DQB1*0602 by genomic nomenclature (Hillert, 1994).
Haines et al. (1998) in a collaborative study, analysed a data set of 98 multiplex MS 
families to test for an association with the HLA-DR2 allele in familial MS and to 
determine whether genetic linkage to the major histocompatibility complex (MHC) was 
caused by such an association. The authors used three highly polymorphic markers 
(HLA-DR, D6S273, and TNF-beta) in MHC demonstrated strong genetic linkage 
(parametric lod scores of 4.60, 2.20, and 1.24, respectively) and a specific association 
with the HLA-DR2 allele was confirmed; the transmission disequilibrium test (TDT) 
yielded a P value of less than 0.001. Stratifying the results by HLA-DR2 status showed 
that the linkage results were limited to families segregating HLA-DR2 alleles. These 
results demonstrated that the HLA-DR2 allelic association could explain genetic linkage 
to the MHC. This study also indicated that sporadic and familial MS share a common 
genetic susceptibility, in addition, preliminary calculations suggested that the MHC 
explains between 17% and 62% of the genetic aetiology of MS (Haines et al., 1998). A 
large number of studies have confirmed the association of MS with a haplotype carrying 
a MHC class II HLA-DR15 and HLA-DQ6 alleles, however, since the original association 
this finding has contributed relatively little to the understanding of disease mechanisms
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(Olerup and Hilled, 1991). Association studies of HLA genes is complicated by the 
presence of highly polymorphic genes and strong linkage disequilibrium, requiring large 
numbers of individuals to be analysed. Masterman et al. (2000) confirmed the 
importance of DRB1*15 susceptibility to MS in 948 Swedish patients, but failed to show 
any influence on either disease course or disease severity. Ligers et al. (2001) showed 
that HLA-DRB1*15 is not the sole MHC determinant of MS susceptibility in northern- 
European populations by finding a similar sharing of linkage in families with and without 
the HLA-DRB1*15 allele. It was pointed out that there remains a possibility that the 
association of MS with HLA-DRB1*15 is due to linkage disequilibrium with a nearby 
locus and/or to the presence of disease-influencing allele(s) in DRB1*15 negative 
haplotypes. Two other studies performed in large pedigrees with a strong family history 
indicated the importance of the HLA-DRB1*15 in conjunction with other haplotypes as a 
modifier in MS susceptibility (Dyment et al., 2001; Vitale et al., 2002). In a study by 
Rubio and co-workers (2002) using log-linear modelling analysis of constituent 
haplotypes that present genomic regions containing HLA class I, II and III genes, it was 
shown that having class I and II susceptibility variants on the same haplotype provides 
an additive risk for MS. It was suggested that by using the approach as outlined in the 
article the contribution of HLA to MS might be defined more accurately.
1.4.2.2 CD45, Protein-Tyrosine Phosphatase, Receptor-Type C
In 3 of 4 independent case-control studies, Jacobsen et al. (2000) demonstrated an 
association between MS and a C-to-G transition at nucleotide 77 in exon 4 of the 
protein-tyrosine phosphatase, receptor-type C (PTPRC) gene. Although the mutation did 
not change the encoded amino acid, it prevented splicing of exon 4 pre-mRNA. 
Furthermore, it was found that the PTPRC mutation was linked to and associated with 
the disease in 3 MS nuclear families. Vorechovsky et al. (2001) determined allele 
frequencies for the 77C-G polymorphism in large numbers of MS patients and patients 
with common variable immunodeficiency (CVID), IgA deficiency (IgAD) and over 1,000 
controls to assess whether aberrant splicing of PTPRC caused by this polymorphism 
results in increased susceptibility to these diseases. They could detect no difference in 
the frequency of the 77G allele in patients and controls in these disorders with a strong
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autoimmune component in aetiology. Likewise, Barcellos et al. (2001), Tchilian et al. 
(2002) and Miterski et al. (2002) found no evidence of genetic association between the 
PTPRC polymorphism and MS susceptibility or disease course. Ballerini et al. (2002) 
detected the 77C-G mutation in a small number of Italian MS patients but not in a 
matched group of healthy controls (Fisher exact test, P value=0.02). This finding 
suggests a role, in at least a group of patients, for the PTPRC mutation in genetic 
susceptibility to MS. Jacobsen et al. (2002) furthermore detected a novel mutation C to 
A at position 59. The mutation interferes with alternative splicing and with antibody 
binding to the CD45RA domain, as previously detected in MS patients (Jacobsen et al., 
2000).
1.4.2.3 Monocyte chemotactic protein 3 (MCP-3)
Monocyte chemotactic protein 3 (MCP-3) is a chemokine that attracts mononuclear 
cells, including monocytes and lymphocytes, the inflammatory cell types that 
predominate in MS lesions. Fitten et al. (1999) have studied the possible association 
between the presence of a CA/GA microsatellite repeat polymorphism in the promoter- 
enhancer region of the MCP-3 gene and the occurrence of MS in the Swedish 
population. They could not determine any significant associations. Nelissen et al. (2002) 
did a follow-up study in the Belgium population and detected a positive association with 
the A3 and a negative association with the A2 allele detected in the promotor area of the 
gene. Further studies are warranted to investigate this association.
1.5 The role of iron metabolism in MS
There are several lines of support for a role of iron dysregulation in MS, which appear to 
be compatible with many processes involved in the pathogenesis of MS. Iron overload 
may predispose individuals to virus infection while inadequate supply of iron may impair 
immune function, thereby influencing the course of infection. The frequency distribution 
of transferrin (an iron- and zinc-binding protein) phenotypes was found to differ in the 
cohort of MS patients and controls studied by Schiffer et al. (1994). Zeman et al. (2000)
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highlighted the potential role of transferrin determination in cerebrospinal fluid (CSF) as 
a means to distinguish between RR, SP and PP MS, and noted that transferrin is also a 
growth factor of importance in proliferation of activated T lymphocytes. Differences in 
iron parameters measured in CSF of MS patients have furthermore been reported by 
several other groups (LeVine et al., 1999; Weller et al., 1999).
Increased mean serum ferritin levels were reported by Valberg et al. (1989) in MS 
patients, although no subjects with clinically manifested hereditary hemochromatosis 
(HH) were recognised by these authors among 1700 patients with MS. Since MS and 
HH affects the same ethnic group, these findings may indicate interaction of the HH 
gene with iron-related genetic and/or environmental factors involved in the MS 
phenotype.
The high demand of iron in the brain and CNS and their sensitivity to iron-induced 
peroxidative damage, suggests the need for stringent regulation of iron availability in 
these organs. Dysregulation of iron homeostasis in the brain may influence the 
myeliniation process, particularly during the early stages of development. The 
importance of sufficient and timely iron delivery to the brain has been repeatedly 
demonstrated (Walter, 1990; Connor and Menzies, 1996), such as the phenomenon of 
hypomyelination in iron-deficient rats (Larkin et al., 1990). Hulet et al. (1999) 
demonstrated that the normal pattern of transferrin and ferritin binding is disrupted in the 
brain tissue of MS patients. This finding provided evidence of ferritin binding in human 
brain and suggests that loss of ferritin binding is involved in or is a consequence of 
demyelination associated with MS. Data on iron concentration in the brains of MS 
patients have been conflicting and, to our knowledge, the possible role of iron has not 
previously been studied at the DNA level. Low or high levels of other heavy metal 
divalent cations have also been associated with the pathogenesis of MS in the past. 
Specifically a report published by Downey (1992) raised the possibility that copper may 
be an environmental risk factor for MS via disturbance of the haem biosynthesis 
pathway.
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1.6 Objectives of the study
The overall objective of the study is to improve our understanding of MS by studying 
genes involved in iron metabolism and immune function within the context of 
autoimmune and infectious disease susceptibility, in order to investigate the complex 
interaction between genetic and viral factors implicated in the pathogenesis of MS.
The specific aims were as follows:
1. Screen MS patients and population-matched controls for genetic variation in 
candidate genes involved in iron metabolism and immune function, in order to 
define a possible link between genetic and environmental factors.
2. Compare frequencies of specific viral sequences among MS subgroups, close 
relatives and unrelated controls to better define possible MS subgroups and 
disease expression within families.
The ultimate goal is to develop a comprehensive molecular diagnostic screening 
approach for detection of a genetic predisposition for MS at an early age, so that 
relevant environmental triggers of the disease can be avoided if possible.
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CHAPTER 2.1
Analysis of the NRAMP1 gene implicated in iron transport: 
Association with multiple sclerosis and age effects.
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ABSTRACT: Multiple sclerosis (MS) is believed to be an autoimmune process occurring in genetically 
susceptible individuals after an appropriate environmental exposure. We have exploited the homogeneous 
Afrikaner population of European ancestry to investigate the likelihood that iron dysregulation, in association with 
infectious and/or autoimmune disease susceptibility, may underlie the MS phenotype in a subgroup of patients. The 
functional Z-DNA forming repeat polymorphism of the natural resistance-associated macrophage protein-1 
(NRAMP1) gene was analyzed in 104 patients diagnosed with MS and 522 Caucasian controls. A family-based 
control group consisting of 32 parental alleles not transmitted to MS offspring was additionally studied to exclude 
the likelihood of population substructures. Statistically significant differences in allelic distribution were observed 
between the patient and control samples drawn from the same population (P <  0.01). Evidence is furthermore 
provided that alleles considered to be detrimental in relation to autoimmune disease susceptibility may be 
maintained in the population as a consequence of improved survival to reproductive age following infectious 
disease challenge. Although it remains to be determined whether the disease phenotype in MS patients with allele 
5 of the NRAMP1 promoter polymorphism is directly related to dysregulation of iron or modified susceptibility 
to viral infection and/or autoimmunity, a combination of these processes most likely underlies the disease 
phenotype in these patients. In view of the emerging role of polymorphic variants in complex diseases and 
minimizing of possible confounding factors in this association study, we conclude that allelic variation in the 
NRAMP 1 promoter may contribute significantly to MS susceptibility in the South African Caucasian 
population. © 2001 Academic Press
INTRODUCTION
The cause of multiple sclerosis (MS), a 
chronic inflammatory disease of the central ner­
vous system (CNS), remains unknown after more 
than a century of study. Current knowledge sug­
gests that MS is associated with autoimmunity, 
with genetic susceptibility and infectious agents 
as important risk factors (1, 2). The overall life­
time risk for siblings of MS patients to manifest 
the disease is estimated at 4-5% , compared to a
population prevalence of approximately 0.1%. Al­
though data on family studies have excluded all 
but a polygenic mode of inheritance, and an au­
tosomal dominant or recessive single locus with 
low penetrance, most evidence suggests that sev­
eral genes control disease susceptibility (3). Au­
topsy studies in a cohort of MS patients indicated 
four fundamentally different patterns of demyeli­
nation, suggesting pathogenetic heterogeneity 
with important implications for the diagnosis and 
treatment of the disease (4).
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Previous genome-wide gene searches and as­
sociation studies suggest that the genetic suscep­
tibility factors of MS may vary between different 
populations (3). The white Afrikaner population 
of South Africa represents an ideal group (5) for 
the identification of genes involved in this com­
plex disease, since the prevalence of MS is rela­
tively high in the European populations that con­
tributed to the gene pool of this genetic isolate. 
Earlier studies indicated a relatively low inci­
dence (~ 0 .4 /l 00,000) of the disease in the Cau­
casian population of South Africa (6), but more 
recently Dean (7) reported that the prevalence of 
MS is on the increase in the Afrikaner population. 
Although the Afrikaner population is mainly of 
Dutch, German and French origin, settlers from 
the United Kingdom with a relatively high prev­
alence (12/100,000) of MS amongst Scottish in­
dividuals (8), have also made a considerable con­
tribution (—5%) to the gene pool (9). The unique 
genetic background of the Afrikaner population 
therefore offers the advantage to study the genet­
ics of MS on the basis of an expected limited 
number of disease-associated genes/mutations in­
troduced from Europe. Genetic analysis in the 
African context furthermore provides the oppor­
tunity to assess the relevance of potentially im­
portant sequence changes in indigenous popula­
tion groups, where MS is considered to be ex­
tremely rare (10).
The importance of genetic factors underlying 
population/ethnic differences in disease risk was 
illustrated by the finding that the hereditary hemo­
chromatosis (HH) mutation C282Y in the HFE 
gene (11), associated with this common iron over­
load disease in the majority (70-100%) o f af­
fected Caucasians worldwide, is virtually absent 
in the South African Black population (12). Of 
relevance to this study is the apparent absence of 
clinically manifested HH among 1700 patients 
with MS encountered by Valberg et al. (13), de­
spite the higher serum ferritin levels detected in 
patients compared with controls and the fact that 
MS and HH affect the same ethnic group. Similar 
findings were reported in an Afrikaner family 
where two sisters with MS were found to be 
homozygous for the common HH mutation 
C282Y (14), which largely excluded the likeli­
hood of a linkage disequilibrium effect with a 
putative MS-related gene on chromosome 6. 
These findings raised the possibility that MS and 
HH may be mutually exclusive due to gene-gene 
interaction in certain populations.
There are several lines o f support for a role of 
iron dysregulation in the pathogenesis of MS (15- 
20). This pertains to the fact that iron overload 
may predispose an individual to virus infection, 
while on the contrary, inadequate supply of iron 
may impair immune function. To further investi­
gate the potential role of iron metabolism in as­
sociation with infectious and/or autoimmune dis­
ease susceptibility in MS, we genotyped 104 
South African MS patients and 532 control indi­
viduals from the same population for the func­
tional Z-DNA forming repeat polymorphism of 
the natural resistance-associated macrophage pro­
tein-1 (NRAMP1) gene. This gene that regulates 
iron, and is also regulated by cellular iron levels 
(21), has been linked to many infectious and au­
toimmune diseases (22-25). Although these find­
ings may be related to any one of the multiple 
pleiotropic effects associated with macrophage 
activation, it seems highly likely that regulation of 
iron transport via NRAMP1 may contribute di­
rectly to disease susceptibility (23). Some of the 
diseases associated with the NRAMP1 gene may 
pathogenetically be related to MS (26-30) and 
apparently also to abnormalities in iron absorption 
(31, 32), that may be linked to defective iron 
supply for erythropoiesis (33). The anemia asso­
ciated with autoimmune disease may be related to 
the proposed role o f NRAMP1 in scavenging iron 
from senescent red cells via splenic macrophage 
phagosomes for transport back to the blood.
MATERIALS AND METHODS
Study population. Relevant information was 
obtained from 281 South African patients, follow­
ing the distribution of a questionnaire that was 
published in the South African National Multiple 
Sclerosis Society newsletter. Blood samples were 
obtained, after informed consent, from 156 South 
African respondents who completed the question­
naire and 197 of their close relatives. The pa­
tients’ neurologists were subsequently contacted
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to verify the MS diagnoses, based on clinical 
features (34), lumbar puncture, magnetic reso­
nance imaging, evoked potentials and/or exclu­
sion of other diseases known to manifest simi­
larly. Uncertain cases included in the study were 
re-examined by J.C. Non-Caucasian South Afri­
can MS patients, recent immigrants, and respon­
dents without a confirmed diagnosis of MS were 
excluded from the study, leaving 104 index cases 
diagnosed with definite MS for genetic analysis.
DNA samples o f 329 South African individ­
uals of European descent (mainly German, Dutch, 
French and British) below the age of 70 years 
were included as unrelated controls. The individ­
uals consisted o f 231 laboratory personnel and 
medical students (68 males and 163 females), and 
98 spouses o f patients with MS (16 males and 13 
females) or familial hypercholesterolemia (34 
males and 35 females). Additionally, 193 elderly 
individuals above the age of 70 years (67 males 
and 126 females) and a family-based control 
group consisting o f 32 parental alleles not trans­
mitted to MS offspring were included for com­
parison within and between subgroups. Inclusion 
and exclusion criteria were similar in the experi­
mental and control groups. MS patients and con­
trols found to be homozygous for the HH muta­
tion C282Y were excluded from this study. Data 
obtained on laboratory personnel, medical stu­
dents and spouses of index cases were pooled 
with the “affected-family-based control” (AF- 
BAC) group (35) after verification of similar al­
lele frequencies in the different groups. DNA 
samples from 448 non-Caucasians (278 Xhosas,
50 KhoiSan, and 120 subjects of Mixed Ances­
try), 37 healthy Scottish individuals and 143 Ger­
mans were included as controls for population 
studies. Matched case-control groups are particu­
larly important in diseases such as MS where 
environmental triggers may be involved. The 
study protocol has been approved by the Ethics 
Review Committee of the University of Stellen­
bosch.
Hematological and biochemical analysis. He­
moglobin, serum iron, transferrin and ferritin con­
centrations were determined using standard meth­
ods. Serum iron was measured with a Beckman
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CX7 autoanalyzer, and transferrin with a Beck­
man array nephelometer. Transferrin saturation 
was subsequently calculated. None of the patients 
analyzed experienced episodes of MS at the time 
iron concentrations were determined.
DNA analysis. Genomic DNA was isolated 
from whole blood using a standard salting-out 
method (36). The PCR primers used to amplify a 
483-bp fragment of the NRAMP1 promoter were 
5 '-GGGGTCTTGGAACTCCAGAT-3' (forward) 
and 5 '-GGGCAGCTCCTCAGCCTGCAC-3' (re­
verse). The PCR conditions were as follows: 200 
ng of genomic DNA, 0.2 ju,M of each dGTP, 
dCTP, dATP, and dTTP, 20 pmol of each primer, 
1.5 mM MgCl2, 10 mM Tris-HCl, 50 mM KC1, 
and 1 U Taq DNA Polymerase. PCR cycle con­
ditions included an initial denaturing step at 95 °C 
for 2 min, followed by 35 cycles at 95°C for 30 s, 
65°C for 45 s, and 72°C for 30 s. Screening of 
PCR-amplified DNA for potential disease-related 
mutations was performed using a combined HEX- 
SSCP (heteroduplex single-strand conformation 
polymorphism) method according to Kotze et al. 
(37). PCR products corresponding to aberrant 
bands were sequenced using an automated system 
(ABI 310, Perkin-Elmer Applied Biosystems). 
For better discrimination between different alleles 
of the (gt)n repeat, Rsal restriction enzyme anal­
ysis was performed according to Graham et al. 
(25). Following the amplification of a shorter 
116-bp fragment using a new reverse primer 5'- 
TACCCCATGACCACACCC-3', PCR products 
were digested to completion with Rsal, subjected 
to polyacrylamide (PAA) gel electrophoresis 
(12% PAA, 5% C), stained with ethidium bro­
mide and visualized by ultraviolet light.
Statistical methods. NRAMP1 allele frequen­
cies were analyzed by STATISTIC A for Win­
dows (38), which offers different statistical meth­
ods to determine significant associations. The 
Chi-square (^2“ ) test and/or Fisher-exact test 
were performed to assess significant associations 
with NRAMP1 in the study population. Due to the 
low frequency of certain variants in the study 
population, the Yates’ correction was applied 
to improve the approximation of the test,
Kotze et al.
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TABLE 1
Biochemical Iron Status Parameters Measured in the Serum 
o f 53 South African MS Patients Classified According 
to Relapsing-Remitting, Secondary Progressive, 
and Primary Progressive Disease Types
Variable
Relapsing- 
remitting 
01 =  34)
Secondary 
progressive 
(» =  10)
Primary 
progressive 
(» =  9)
Mean SD Mean SD Mean SD
Age (years) 40.3 10.9 46.4 12.1 47.8 7.1
S-iron (/imol/liter) 17.0 6.8 17.8 6.8 16.6 6.4
Transferrin (g/liter) 2.8 0.4 2.9 0.4 2.6 0.4
Transf sat (%) 25.1 10.6 25.4 12.0 25.4 10.0
Ferritin (/xg/liter) 77.9 63.5 117.0 83.1 171.8* 135.7
* Relapsing-remitting vs primary progressive MS: P  =  0.04.
thereby providing a more conservative estimation. 
The Arlequin program (39) was used to test for 
various associations of polymorphic variants in 
the disease and control populations. This program 
assesses the likelihood that false associations may 
be obtained due to population substructures. For 
continuous variables groups were compared using 
unpaired t tests. The Wilcoxon (Kruskal-Wallis) 
and median tests were used for variables (ferritin) 
with skew distributions.
RESULTS
Serum Iron Parameters
Iron parameters were determined in 34 South 
African MS patients with relapsing-remitting 
(RR) MS, 10 with secondary progressive (SP) MS
and 9 with primary progressive (PP) MS. Similar 
to that of a control group including 30 Caucasian 
individuals, the hemoglobin, serum iron, trans­
ferrin, transferrin saturation and ferritin values 
were within the normal range in the majority of 
cases. The serum ferritin concentration was sig­
nificantly lower in the RR group than in the PP 
group (P <  0.05), but none of the other param­
eters tested differed between the three patient 
groups (Table 1). When males are excluded, the 
statistical significance disappears even though the 
trend remains the same (RR 71.6 /xg/liter, SP 88.0 
l±g/liter, PP 109.6 /xg/liter). The patients with the 
progressive illness showed greater variability in 
ferritin levels. Patients with a RR disease course 
were the youngest on average (P <  0.08). The 
age at onset was also the youngest in the RR MS 
group (29.5, SD 9.6), followed by the SP (34.3, 
SD 11.1) and PP (35.3, SD 6.8) groups.
Analysis o f  the Functional Z-DNA Forming 
NRAMP1 Repeat Polymorphism
Many variants have been described in the 
NRAMP 1 gene, one o f which is a functional 
Z-DNA forming repeat promoter polymorphism 
affecting NRAMP 1 expression (22). The different 
alleles detected within the amplified DNA frag­
ment spanning this polymorphic region are shown 
in Table 2, together with the allelic distribution 
observed in South African Caucasian MS patients 
and controls drawn from the same population. 
The allelic distribution of the Z-DNA forming
TABLE 2
Comparison o f Allelic Distribution between South African MS Patients (22 Males, 82 Females) and Controls
Controls
Alleles MS patients General AFBAC Elderly Total
2 41 (20%) 223 (34%) 11(34%) 86(22% ) 320(30%)
3 160(77%) 434(66% ) 21(66% ) 297(77% ) 752(70% ) 
5 7(3% ) 1(0.1%) 0 3(0.8%)* 4(0.4%)** 
Total 208 658 32 386 1076
Note. NRAMP 1 alleles are numbered according to Ref. 25. The controls (1076 alleles) are grouped according to “affected family-based 
control” (AFBAC), general population-matched controls (118 males, 211 females), and elderly subjects (67 males, 126 females).
* General control group vs elderly subjects: P  <  0 .01, 2 df, \ 2 =  16.6.
** MS vs total control group: P  <  0 .01, 2 df, \ 2 =  35.2; MS vs general control group: P  <  0 .01 , 2 df, \ 2 =  30.8; MS (16 
patients) vs AFBAC (32 parental alleles): P  <  0 .01, 2 df, \ 2 =  43.79; MS vs elderly control group: P  =  0 .05, 2 df, x 2 =  5.7.
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TABLE 3
Clinical Characteristics o f  South African MS Patients with NRAMP1 Allele 5
Relatives with definite MS
Index patients (n =  7) (« = 2)
Patient numbers 43 58 67 70 73 81 90 Sister o f 43 Aunt of 81
Gender F F F F M F F F F
Age (years) 48 38 27 35 45 27 29 39 50
Age o f onset (years) 38 24 20 32 41 23 15 15 23
Age at diagnosis (years) 41 30 24 33 42 23 23 25 46
Disease course RR RR RR RR SP RR RR RR SP
Iron parameters"
Hemoglobin (11.5-16.5 g/dl) 13.5 15.0 14.4 12.6 14.0 12.0 13.7 ND 13.6
Serum iron (6-32 /xmol/liter) 11.0 14.2 23.3 21.5 16.3 29.7 16.1 ND 17.1
Transferrin (1.8-3.8 g/liter) 3.0 2.4 3.0 3.1 2.3 2.5 3.0 ND 2.4
Transferrin saturation (15-50%) 15 24 31 30.3 28 52.7 21 ND 31
Ferritin (12-119 /xg/liter) 33.5 88.8 70.2 157.9 329.5 216.6 14.5 51.2 77.3
Note. F, female; M, male; RR, relapsing-remitting; SP, secondary progressive; ND, not determined.
“ Reference values for males: hemoglobin, 12.5-17.5 g/dl; serum iron, 7-35 /xmol/liter; transferrin, 1.8-3.8 g/liter; saturation, 20-50%; 
ferritin, 29 -396  jag/liter.
dinucleotide polymorphism differed significantly 
between the MS patients and population-matched 
controls (P <  0.01), including 329 individuals 
from the general population within the same age 
group, a family-based control (AFBAC) group 
including 32 parental alleles not transmitted to 
MS offspring, and 193 elderly Afrikaner individ­
uals above the age of 70 years. Although the 
sample sizes of the different subgroups analyzed 
are relatively small, no population substructures 
were evident upon application of the Ewens- 
Watterson test of selective neutrality and the 
Chakraborty’s test for population amalgamation 
(39). The genotype distribution and allele fre­
quencies of the NRAMP1 promoter variant were 
in Hardy-Weinberg equilibrium in the popula­
tions tested.
Genotyping of the 193 elderly Afrikaner indi­
viduals from the general population also indicated 
a significant deviation from the younger control 
group (P  <  0.01) (Table 2). This finding sug­
gests that alleles considered to be detrimental in 
relation to autoimmune disease susceptibility may 
be maintained in the population because they im­
prove survival to reproductive age following in­
fectious disease challenge (22), a phenomenon 
that may be of particular relevance in the African 
context. This may imply that alleles 3 and 5 found 
at a higher frequency in the elderly group com­
pared to younger controls might confer protection 
against infection, iron overload and/or oxidative 
processes implicated in aging. Iron deficiency 
anemia was evident in the two elderly males (fer­
ritin, 12 and 39 /xg/liter; transferrin saturation, 
10.8 and 16.5%) with this genotype, while higher 
levels (ferritin, 273 ju-g/liter; transferrin saturation, 
20%) were measured in the elderly female with 
alleles 3 and 5 o f NRAMP1.
The clinical characteristics of the index MS 
patients with allele 5 are summarized in Table 3, 
together with that o f two affected female relatives 
with this allele who were also diagnosed with 
definite MS. Extended clinical and family follow 
up are underway to clarify the potential role of 
NRAMP1 in the MS phenotype.
Population Studies
NRAMP1 allele 5 was not detected in Afri­
cans following DNA screening o f 278 Xhosas, 50 
KhoiSan, and 120 subjects of Mixed Ancestry. 
This finding is in accordance with the potential 
significance of allele 5 in MS, since this disease is 
extremely rare in Africans (10). Population and 
haplotype studies using intragenic NRAMP1 
polymorphisms are in progress to trace the origin 
of NRAMP1 allele 5 in European populations that 
contributed to the Afrikaner gene pool. Prelimi­
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nary data obtained in DNA samples of healthy 
Scottish individuals indicated a significantly 
higher frequency (2/37, 5.4%) of NRAMP1 allele 
5 in this population compared with the general 
Afrikaner population (0.3%) (P <  0.01, 2 df, 
X2 =  14.33), while an intermediate frequency 
was observed in the German population (3/143, 
2.1%). These findings raise the possibility that 
NRAMP1 allele 5 may be one of the factors 
underlying the high prevalence (8) of MS in Scot­
land. Approximately 15% of the 104 South Afri­
can MS patients (1/7 with allele 5) included in this 
study reported that at least one of their ancestors 
was of Scottish descent.
DISCUSSION
Iron is an essential nutritional element for 
normal cellular functioning of a large number of 
enzymes, including those involved in myelin for­
mation, neurotransmitter synthesis and degrada­
tion, oxidative phosphorylation and heme biosyn­
thesis (40-42). Hemeproteins are involved in 
electron transport, which could be critical to ax­
onal as well as to myelin integrity. The human 
NRAMP1 gene was analyzed in this study as a 
first candidate to investigate the hypothesis that 
intermittent iron deficiency (19) may underlie the 
MS phenotype in a subgroup of patients. The 
potential value o f iron concentration determina­
tion in the cerebrospinal fluid (CSF) in distin­
guishing between MS patients with different dis­
ease courses has been demonstrated (16, 17), and 
this may also apply to determination of serum iron 
parameters (20). Preliminary data furthermore in­
dicated a significantly higher mean serum ferritin 
concentration in the South African patient group 
compared to controls (data not shown), which is 
in accordance with previous findings (13). This 
difference remained statistically significant when 
only females were compared, and in this group 
mean transferrin saturation was lower in patients 
compared with controls, although the values were 
within the normal range in both groups. The sta­
tistically significant differences in NRAMP1 al­
lelic distribution observed between MS patients 
and control individuals drawn from the same pop­
ulation (P <  0.01) are in accordance with pos­
sible involvement of iron metabolism in the 
pathogenesis of MS. Notably, different cellular 
iron levels in Nrampl wild type (low) versus 
mutant (high) macrophages in mice may affect 
mRNA stability for MHC class II molecules (23), 
which highlights the link between iron metabo­
lism and cell-mediated immunity (43). The en­
hanced responsiveness of Nramp 1 wildtype mac­
rophages to a range of biological stimuli (44), 
including bacterial lipopolysaccharide (LPS), in- 
terferon-y, glucocorticoids such as dexametha- 
sone or cortisone (frequently applied in the treat­
ment of MS), may relate to the enhancer activity 
of the Z-DNA forming dinucleotide repeat (22) 
analyzed in this study.
The functional significance of the NRAMP 1 
promoter polymorphism analyzed argues against 
the likelihood that the increased frequency of the 
potentially functional Z-DNA variant in South 
African MS patients is due to association with 
another mutation in the NRAMP 1 gene or a 
nearby gene. Sequence changes which directly 
affect the gene product are more likely to dem­
onstrate genetic and phenotypic differences be­
tween patient and control samples than indirect 
markers, particularly if  it is present in only a small 
proportion o f the study population as demon­
strated in this study. This may explain why pre­
vious investigators failed to identify human chro­
mosome 2q as a potentially important region in 
whole genome screens for MS and highlights the 
potential involvement of separate candidate loci 
in different populations (3). Association studies 
appear to be of greater power than linkage anal­
ysis in genetic studies of complex human diseases 
(45), since associated (disease-predisposing) 
polymorphisms are not necessarily linked to a 
disease. A mathematical explanation for this phe­
nomenon has been provided by Greenberg (46), 
which emphasizes the fact that the detection of 
certain alleles (usually at a lower frequency) in a 
control population does not exclude the likelihood 
that the sequence change may cause or contribute 
to the disease phenotype. MS is considered to be 
a heterogeneous disease (4, 47) where many dif­
ferent genes may be defective. Consistent linkage 
to the HLA region on chromosome 6 (47) in 
different genomic data sets and different popula­
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tions may be related to possible polygenic control 
of MS, where disease susceptibility in conjunc­
tion with environmental factors is determined by 
non-MHC genes and disease severity/course by 
modulation o f T cell responses to particular anti­
gens, much like the situation described in mice 
(48). Interestingly, Jacobsen et al. (49) have re­
cently demonstrated an association between MS 
and the gene (PTPRC) encoding protein-tyrosine 
phosphatase, receptor-type C (CD45), known to 
be essential for the activation of T and B cells.
The many cellular functions dependent on 
iron and other metal ions as cofactors may explain 
the complex role of NRAMP 1 in infectious and 
autoimmune disease. Future studies may reveal 
whether the frequent co-existence of MS and in­
flammatory bowel disease (26, 27), which share 
some common features (28), may be explained by 
the involvement of the NRAMP 1 gene in both 
conditions (24). The increased frequency of allele 
5 of the Z-DNA forming polymorphism detected 
in patients with primary biliary cirrhosis (PBC) 
studied by Graham et al. (25), further supports the 
view that PBC and MS may be related by a 
similar autoimmune process (29). The likelihood 
that the relatively high frequency of allele 5 de­
tected in the South African MS cohort is caused 
by coexistence o f PBC, was largely excluded by 
previous studies performed by Reich et al. (50), 
recently extended to our study population.
None o f the South African MS patients with 
NRAMP 1 allele 5 was anemic, which highlights 
the fact that standard parameters of iron status 
may not necessarily reflect abnormalities in iron- 
related genes (51, 52). Expression o f iron-related 
genes is furthermore modulated by environmental 
(e.g., diet, the menstrual cycle, multiple pregnan­
cies, regular blood donation) and genetic factors 
(53), as demonstrated by frequent detection of 
clinically unaffected subjects with the HH geno­
type, even in the elderly population (54). It is well 
known that a significant inflammatory process can 
cause interference of iron delivery for heme syn­
thesis resulting in altered iron levels, such as 
raised ferritin levels and decreased transferrin sat­
uration. Two index cases with a family history of 
MS and their two female relatives diagnosed with 
definite MS reported porphyria-like symptoms
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similar to those described by Rooney et al. (19), 
supporting the hypothesis that a disturbance of the 
heme biosynthesis pathway may be involved in 
the etiology of MS in a subgroup of patients. The 
likelihood that the allelic association described 
here may only be due to the atypical porphyria­
like symptoms and is unrelated to MS per se, was 
largely excluded by the fact that only two of 
the five remaining allele 5-positive index cases 
without a family history of MS reported similar 
symptoms.
The data presented in this study are consistent 
with pathogenic roles for iron-related gene-envi- 
ronment interactions in MS and the previous spec­
ulation (22) that certain detrimental NRAMP 1 
alleles related to autoimmune disease susceptibil­
ity, may be associated with improve survival. 
Although it remains to be determined whether the 
disease phenotype in patients with NRAMP 1 al­
lele 5 is directly related to dysregulation of iron or 
modified susceptibility to viral infections and/or 
autoimmunity, a combination o f these processes 
most likely underlie the disease phenotype in a 
subgroup of South African MS patients with the 
potential disease-predisposing promoter variant. 
In view of the emerging role o f polymorphisms in 
complex diseases (55), the functional significance 
of the Z-DNA forming NRAMP 1 dinucleotide 
repeat in autoimmune and infectious disease sus­
ceptibility linked to iron regulation, and minimiz­
ing of possible confounding factors in this asso­
ciation study, we conclude that allelic variation in 
the NRAMP 1 promoter may contribute signifi­
cantly to MS susceptibility in the South African 
population of European descent. A prominent role 
of iron in the etiology of many neurological dis­
eases may be forthcoming via its role as a co­
factor of hemeproteins which, when dysfunc­
tional, may give rise to deficiencies in energy 
production, axonal degeneration and porphyric 
neuropathy (56-58).
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CHAPTER 2.2
Association study of the functional GT-repeat polymorphism 
in the promoter region of the SLC11A1 gene in German and 
French patients with multiple sclerosis
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Association study of the functional GT-repeat polymorphism 
in the promoter region of the SLC11A1 gene in German and 
French patients with multiple sclerosis
ABSTRACT
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. 
Support for a role of iron metabolism in MS was obtained in a recent study of the gene 
encoding the solute carrier family 11 (proton-coupled divalent metal ion transporters) 
member 1 (SLC11A1), formerly known as the natural resistance-associated 
macrophage protein (NRAMP1), in the genetically homogeneous Afrikaner population of 
South Africa. In this study the proposed allelic association with SLC11A1 was further 
investigated in MS patients from Germany and France, representing two of the parent 
populations that contributed significantly to the gene pool of the Afrikaner population. 
The German study population consisted of 267 German MS patients, subdivided into 
three groups according to disease course, and 176 population-matched controls. The 
French study group included 107 MS simplex families subjected to transmission 
disequilibrium testing (TDT) for the functional 5’-(GT)n repeat polymorphism in the 
promoter region of the SLC11A1 gene. No allelic association between this 
polymorphism and MS could be detected in the case-control or family studies. However, 
the German patient group demonstrated statistically significant differences in genotype 
distribution between patients with primary- and secondary-progressive MS (P<0.05), and 
between patients with relapsing remitting- and primary progressive MS (P<0.05). These 
findings raise the possibility of a complex interplay between SLC11A1 and 
environmental factors such as infectious agents and/or iron status, known to affect gene 
expression. SLC11A1 may serve as a model for various diseases where gene- 
environment interaction results in a relatively small effect with regard to familial risk but a 
large effect on population risk.
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INTRODUCTION
The aetiology of multiple sclerosis (MS) is unknown, although it is widely regarded as an 
autoimmune disease. It primarily affects young adults, particularly women. Three clearly 
distinguishable disease courses have been defined (Lublin and Reingold, 1996), namely 
relapsing-remitting (RR), secondary-progressive (SP) and primary-progressive (PP). In 
patients with RR disease, episodes occur with unpredictable frequency, variable 
severity, and often with residual neurological deficits. In 50-60% of patients with RR MS 
the disease course converts to gradual progression, again at different rates in different 
patients. In these patients with SP MS, superimposed relapses may occur, particularly 
early in the SP phase. PP disease is observed in a small minority of MS patients without 
any clear-cut relapses or sustained periods of improvement. Although PP MS has less 
inflammatory activity on magnetic resonance imaging (MRI) and histopathological 
examinations (Thompson et al., 1997), the histopathological picture varies greatly within 
disease types (Storch and Lassmann, 1997). It is not clear whether the differences in 
the clinical course and pattern of MRI abnormalities between RR and SP phases 
represent different immunopathologic processes or mechanisms, or are simply a result 
of repeated clinical and subclinical relapses and cumulative damage to the central 
nervous system (CNS). Since disease types cannot be subclassified by MRI, a 
combination of precise clinical descriptions of disease courses and MRI appearance, 
possibly in conjunction with immunological, virological and/or genetic analysis, may be 
the only way of subgrouping MS.
LeVine et al. (1999) have demonstrated the potential value of iron concentration 
determination in the cerebrospinal fluid (CSF) in distinguishing between chronic 
progressive and RR MS. This was substantiated in a recent study including analysis of 
serum transferrin concentrations in MS patients, demonstrating frequent detection of 
subnormal values in PP patients in comparison with the SP form and RR form in 
remission (Zeman et al., 2000). The transferrin index was furthermore significantly 
higher in patients with PP MS than in patients with RR or SP disease courses, while the 
transferrin quotient was significantly more frequently subnormal in patients with RR MS
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in remission compared to those experiencing attacks. CSF transferrin and transferrin 
quotient were furthermore higher in male than in female patients. These findings 
suggest an important role of iron metabolism in the aetiology of MS, which appear to be 
in accordance with gender-related differences in iron status that may relate to the fact 
that MS is more common in females than males (2:1).
Further support for a role of iron homeostasis in the pathogenesis of MS was obtained 
from a recent study performed in the relatively genetically homogenous Afrikaner 
population of South Africa, demonstrating a significant association with the gene 
encoding the solute carrier family 11 (proton-coupled divalent metal ion transporters) 
member 1 (SLC11A1), formerly known as the natural resistance-associated 
macrophage protein (NRAMP1) (Kotze et al., 2001). SLC11A1 has been linked to 
various autoimmune and infectious diseases, which led to speculation that regulation of 
iron by SLC11A1 may be of major importance in this context (Blackwell et al., 2000). We 
have recently provided direct support for this hypothesis, when functional studies 
demonstrated increased expression upon iron loading for allelic variants 3 and 5 
(Graham et al., 2000) of the SLC11A1 promoter polymorphism shown to be associated 
with MS in South Africa (Kotze et al., in press). The unique genetic background of the 
Afrikaner population including Dutch (34.8%), German (33.7%), French (13.2%) and 
British (5.2%) origins (Botha and Beighton, 1983), provided the advantage to study the 
genetics of MS on the basis of an expected limited number of disease-associated 
genes/mutations introduced from Europe. This gene pool remained relatively isolated 
during the establishment of around 14 generations since the arrival of the first 
immigrants from Holland at the Cape more than 330 years ago. The aim of the present 
study was to further investigate the association detected between MS and the SLC11A1 
gene in other populations that contributed to the gene pool of the South African 
Afrikaner population.
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SUBJECTS AND METODS
The diagnosis of MS in affected patients was based on clinical features (Poser et al., 
1983), magnetic resonance imaging (MRI) and/or exclusion of other diseases known to 
manifest similarly.
German study group
Blood samples were obtained with informed consent from 267 German MS patients, 
attending an outpatient clinic at the University Hospital Eppendorf in Hamburg. These 
individuals included 129 patients with a RR disease course, 75 with SP and 63 with PP 
MS. DNA samples of 176 healthy German individuals kindly provided by Dr Herbert 
Schuster were included as controls.
French study group
A total of 109 case-parent MS families, all comprising one affected child with definite MS 
and two healthy parents, were recruited throughout France by the French Multiple 
Sclerosis Genetic Group. Written consent was obtained from each individual 
participating in the study in accordance with the Helsinki Convention and the French law 
relating to biomedical research. Geographic and ethnic origin, sex, age at onset, 
duration of the disease, disease course and grading in a MS disability scale were 
recorded for each patient.
DNA analysis
Genomic DNA was extracted using standard methods and subjected to polymerase 
chain reaction (PCR)-amplification using primers (15pmol), 5’ -  ggggtcttggaactccagat- 3’ 
(forward) and 5’ -taccccatgaccacaccc -3 ’ (reverse) spanning the 5’-(GT) repeat 
polymorphism in the SLC11A1 promoter region. The PCR was performed in a 25 pi 
reaction volume containing 50 ng of genomic DNA, 0.2 pM of each dGTP,dCTP,dATP 
and dTTP, 1.5 mM MgCI2, 10 mM Tris-HCI, 50 mM KCI and 0.5 U Taq DNA Polymerase 
(Roche - Diagnostics, Germany). PCR cycle conditions included an initial denaturing 
step at 95°C for 2 min, followed by 40 cycles at 95°C for 30 s, 60°C for 45 s, and 72°C
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for 30 s and performed on a 9700 thermal Cycler (ABI, Foster City, CA, USA). The PCR 
products were digested to completion with 5 U Rsa\ (Gibco, Gaithersburg, Md, USA) as 
described by Graham et al. (2002), and subjected to polyacrylamide (PAA) gel 
electrophoresis (12% PAA, 5% C), stained with ethidium bromide and visualised by 
ultraviolet light.
Statistical analysis
Statistical analysis was performed in the German study population by STATISTICA for 
Windows (StatSoft Inc. Tulsa OK, USA). Two-tailed Fisher exact test and the x2 
calculation were applied as appropriate. Due to the low frequency of genotypes 22 and 
35 it was excluded to obtain a statistically viable sample size (table 1). The transmission 
test for linkage disequilibrium (TDT) was performed in the French families as described 
by Spielman et al. (1993). P-values <0.05 were regarded as statistically significant.
RESULTS AND DISCUSSION
Analysis of the 5’-(GT)n repeat polymorphism in the promoter region of the SLC11A1 
gene in 267 German and 107 French patients diagnosed with definite MS, did not reveal 
statistically significant associations in either the German case-control study or in the 
French simplex families using TDT. However, when genoptype comparisons were made 
between German MS patients subgrouped according to disease course, a statistically 
significant difference (P<0.05) was detected between patients with SP and PP MS (table 
1). A significant difference in genotypic distribution was also observed between the 
German patients with a RR and PP disease course (P<0.05). No significant differences 
were observed when the allele frequencies were compared between these MS patient 
groups (data not shown).
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Table 1: Comparison of genotype distribution for the SLC11A1 GT-repeat polymorphism 
among controls and German MS patients subdivided according to disease course.
Genotype
2 [t(gt)5ac(gt)5ac(gt),0g]
3 [t(gt)5ac(gt)5ac(gt)9g]
5 t(gt)4ac(gt)5ac(gt)10ggcaga(g)]
Controls
German MS patients
Relapsing
remitting
(RR)
Secondary
progressive
(SP)
Primary
progressive
(PP)
Total MS
2/2 4 (2%) 4 (3%) 0 1 (2%) 5 (2%)
2/3 74 (42%) 40 (31%) 25 (33%) 31 (49%) 96 (36%)
3/3 96 (54%) 83 (64%) 50 (67%) 31 (49%) 164 (61%)
3/5 2 (2%) 0 0 2(1%)
Total 176 129 75 63 267
Alleles are numbered according to Graham et al. (2000). 
RR MS vs PP MS: P<0.025, 1 df, y 2 = 5.33 
SP MS vs PP MS: P<0.05, 1 d f, x = 3.9
Failure to detect significant associations in the French families (table 2) may be due to 
the fact that TDT generally has a lower power than association studies based on case- 
control samples (Spielman and Ewens, 1996). SLC11A1 allele 5 implicated as an 
important risk factor in South African MS patients (Kotze et al., 2001), was detected in 
only three of the 107 French families studied and in one of these cases this allele has 
not been transmitted from the mother to the MS affected individual. Allele 3, known to be 
associated with autoimmune disease susceptibility in general (Searle and Blackwell, 
1998; Blackwell et al., 2000) and with MS in the South African population (Kotze et al.,
2001), was more frequently transmitted to the affected offspring, but this was not 
statistically significant. Our previous finding indicating a significant association between 
the 5’-(GT)n repeat polymorphism of the SLC11A1 gene and MS in the South African 
population (Kotze et al., 2001), is in accordance with the assumption that the Afrikaner 
population of European descent represents a valuable source of material for mapping 
studies to identify genes involved in complex diseases.
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Table 2: Association analysis of the SLC11A1 GT-repeat polymorphism in 107 French 
simplex MS families________________________________
Alleles French simplex MS families 
Transmitted Non-transmitted
1 [ttetkactat^acteOng] 0 1
2 [t(gt)5ac(gt)5ac(gt)10g] 51 56
3 [t(gt)5ac(gt)5ac(gt)9g] 161 156
5 t(gt)4ac(gt)5ac(gt)10ggcaga(g)] 2 1
Total 214 214
Alleles are numbered according to Graham et al. (2000).
Detection of SLC11A1 allele 5 in both the German and French populations confirmed 
the European origin of this variant (Graham et al., 2000). It is noteworthy that the highest 
frequency (5.4%) reported to date for SLC11A1 allele 5 occurs in the Scottish 
population, reported to have a genetic predisposition for MS (Rothwell and Charlton, 
1998, Graham et al., 2000). This allele appears to be absent in Africans, a finding which 
has previously been related to the virtual absence of MS in this ethnic group (Kotze et 
al., 2001). Failure to clearly demonstrate an association between SLC11A1 and MS in 
the European populations studied, may be a consequence of selection criteria and 
differences in environmental exposures in the different populations.
The data provided in this study raise the possibility of a complex interplay between 
SLC11A1 and environmental factors in the aetiology of MS, which may include 
infectious agents and iron status known to affect gene expression (Searle and Blackwell, 
1998, Kotze et al., in press). It seems likely that the observed differences in allelic 
distribution of the 5’-(GT) promoter polymorphism among German MS subgroups reflect 
interaction of the gene with such potential modifiers of MS susceptibility or progression. 
Differing environmental exposures interacting with SLC11A1 might furthermore 
contribute to the failure to demonstrate an association between the SLC11A1 gene 
promoter polymorphism and MS in the French patients using TDT. SLC11A1 may 
therefore serve as a model for various diseases where interaction of the gene with 
infectious agents and/or iron as modifying factors may have a relatively small effect on 
familial risk but a large effect on population risk.
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CHAPTER 2.3
Analysis of South African patients with multiple sclerosis: 
Population versus familial risk associated with the presence 
of viral sequences
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Analysis of South African patients with multiple sclerosis: 
Population versus familial risk associated with the presence 
of viral sequences
ABSTRACT
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS). Although current knowledge suggests that MS is associated with autoimmunity, 
and that genetic susceptibility and infectious agents may be involved in the disease 
process, the cause of MS remains unknown. Recent studies performed in the South 
African population demonstrated a significant association between MS and the 
functional 5’-(GT)n polymorphism in the promoter region of the SLC11A1 gene 
implicated in both autoimmune and infectious disease susceptibility. In this study serum 
and peripheral blood mononuclear cells (PBMCs) of MS patients, close relatives and 
unrelated controls were screened for the presence of MS-associated retrovirus (MSRV) 
and two herpes virus (HHV-6 and EBV) sequences, respectively, within the context of 
the SLC11A1 genetic background. Viral sequences were not confined to a specific 
SLC11A1 genotype, thereby excluding the possibility that SLC11A1 allele 2 previously 
implicated in susceptibility to infectious diseases, correlates with viral infection in MS 
patients. Expression of the pol gene of MSRV was detected in the serum RNA of 34/49 
(69%) MS patients and 23/33 (70%) of their unaffected close relatives, whilst absent in 
the serum of 39 unrelated healthy control individuals (P0.001). No significant 
differences were observed with respect to presence or absence of EBV sequences. 
HHV-6 sequences were detected at a significantly lower frequency (P<0.04) in the 
PBMCs of unrelated controls (5%) compared with the MS patients (22.5%), most of 
whom also expressed MSRV RNA. The data provided in this study indicated that virus 
infections mostly affect the population risk and not the familial risk in MS.
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INTRODUCTION
There is a considerable interest in the theory that exposure to a virus may lead to an 
immunopathologic condition resulting in multiple sclerosis (MS). Numerous infectious 
agents, both viral and bacterial, have been implicated in the aetiology of MS, but to date 
no infectious agent has been consistently found in affected patients (Cook et al., 1995). 
Some viruses produce superantigens capable of T-cell stimulation, which may result in 
an autoimmune process. A clear link has been shown between virus infection, 
autoimmunity and neurological disease in patients with human T-lymphotropic virus type 
1-associated myelopathy/tropical spastic paraparesis, a disease that may be 
indistinguishable from MS (Levin et al., 2002). Molecular mimicry, a process whereby an 
immune response is mediated against an environmental agent that cross-reacts with a 
host antigen, has been proposed as another possible explanation for MS (Levin et al.,
2002). In this case an antiviral response may be triggered against myelin due to 
molecular mimicry between viral proteins and proteins of the central nervous system 
(CNS). It has been shown that the myelin basic protein (MBP) shares extensive 
homologies at the amino acid level with a number of common pathogens, including 
measles, hepatitis B, influenza virus, adenovirus, Epstein-Barr virus (EBV) and 
papillomavirus.
Viruses such as the EBV that can establish persistent or latent infections in the CNS or 
the immune system are attractive candidates as aetiological agents in a chronic 
neurological disorder such as MS (Myhr et al., 1998). In a meta-analysis of published 
investigations, it was estimated that the odds of disease are more than 10 times higher 
in EBV-positive than EBV-negative individuals (Ascherio and Munch, 2000). Wandinger 
et al. (2000) have reported that active viral replication occurs more commonly in MS 
patients with exacerbations than in patients with stable disease. The known association 
between MS and the HLA class II protein, recently shown to act as a cofactor of EVB 
infection in B lymphocytes (Li et al., 1997), furthermore suggests a common genetic 
predisposition. However, in a study of long-term EBV-negative adult MS patients, the 
distribution of the DR2 alleles commonly associated with MS was similar to that of EBV-
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seropositive adults (Jabs et al., 1999), which argues against the role of genes to explain 
the EBV association with MS. Since only a small proportion of individuals infected with 
EBV develop MS, it is clear that other cofactors are required, which may include age at 
primary infection or co-infection with other microbes. The finding that variant A of the 
human herpesvirus-6 (HHV-6) may infect EBV-positive B-cell lines and activate the 
latent EBV genome (Cuomo et al., 1995), suggest that interactions between 
herpesviruses may play a role in the pathogenesis of MS (Akhyani et al., 2000). Perron 
et al. (1997) have described a novel MS-associated retrovirus (MSRV) in patients with 
MS that was absent in control individuals, and has subsequently demonstrated (Perron 
et al., 2000) that endogenous retroviral elements are integrated into human 
chromosomal regions previously implicated in susceptibility to MS. A complex multi-step 
aetiology of MS is therefore proposed, involving triggering of specific genetic elements 
by EBV or other infectious agents.
The role of genetic influences in MS susceptibility has been demonstrated (Ebers et al., 
1995), but there is controversy as to which genes are involved. The major 
histocompatibility (MHC) loci, particularly class II, as well as genes controlling T-cell 
receptors and cytokines, appear to be important. In a recent study performed in the 
genetically relative homogeneous Afrikaner population of South Africa, Kotze et al. 
(2001) reported an association between MS and the gene encoding the solute carrier 
family 11 (proton-coupled divalent metal iron transporters) member 1 (SLC11A1), 
formerly known as the natural resistance-associated macrophage protein 1 (NRAMP1) 
gene. Subsequent in vitro studies to determine the effect of iron loading on allelic 
expression of the functional Z-DNA forming polymorphism in the promoter region of the 
gene, provided a direct link between iron homeostasis and autoimmune versus 
infectious disease susceptibility (Kotze et al., in press). Since SLC11A1 regulates iron 
and is also regulated by iron, this gene may serve as a model for various diseases 
where interaction with iron as a modifying (environmental) factor may have a relatively 
small effect on familial risk but a large effect on population risk.
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The aim of the present study was to screen for the presence of MSRV and two herpes 
virus (HHV-6 and EBV) sequences in serum and/or peripheral blood (PBMC) of MS 
patients and population-matched controls, to investigate the possible role of these 
agents as environmental inducers of MS in genetically susceptible individuals. 
Comparison of frequencies of specific viral sequences among MS patients, close 
relatives and unrelated controls were performed within the context of the SLC11A1 
genetic background, in an attempt to provide a better definition of MS subgroups and 
disease expression within specific families.
SUBJECTS AND METHODS
Study population
Blood samples were obtained with written informed consent from 104 unrelated South 
African MS patients of European descent and their close family members (parents, 
spouses and siblings). Prior to inclusion in this study, all individuals have been 
genotyped for the '5-(GT)n repeat polymorphism in the promoter region of the SLC11A1 
gene (Kotze et al., 2001). The diagnoses of MS in affected patients were based on 
clinical features (Poser et al., 1983), magnetic resonance imaging (MRI) and/or 
exclusion of other diseases known to manifest similarly. The samples obtained form 49 
MS patients and 33 of their close relatives were subjected to viral analysis in the present 
study. The unrelated control population consisted of 39 individuals, including laboratory 
personnel and healthy blood donors within the same age- and population group. The 
Ethics Review committee of the University of Stellenbosch approved the study protocol.
DNA and RNA extraction
Genomic DNA was isolated from EDTA-preserved whole blood using a standard salting- 
out method (Miller et al., 1988). DNA concentrations were quantified and diluted to a 20 
ng/jj.1 working solution. RNA was prepared from 140 [i\ serum using the QIAamp viral 
RNA purification kit according to the manufacturers’ protocol (QIAGEN GmbH, 
Germany).
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Amplification of virus sequences
A portion of the internal repeat sequence (Bam H1 W-fragment) of the EBV genome was 
amplified using the polymerase chain reaction (PCR) as described by van Heerden et al. 
(1995), with minor modifications. In the second round of amplification, 3 pi of the product 
generated during the first round was used as template. A cell lysate preparation of the 
EBV containing Raji cell line was used as positive control. The PCR results were 
confirmed by overnight spot blot hybridisation (van Rensburg et al., 1996) to the DIG- 
labelled Bam H1 W-fragment at 55°C.
For detection of HHV-6 sequences in peripheral blood lymphocytes, a 249-bp fragment 
was amplified in a first-round PCR using primers A and B as described (Aubin et al., 
1991). The second round of amplification was performed by using 2 pi of the first round 
product. Primer B from the first round and primer 5U (5’-GCGAAGGGCTGATTAGGAT- 
3’) (Kempf et al., 1995) was used as primer pair for the second round of amplification. 
The 50 pi PCR reaction mixtures contained 3 mM MgCh and 1 U Taq polymerase 
enzyme. The annealing temperature for both the first and second round amplifications 
was 55°C. A DIG-labelled plasmid probe (HHV6M) containing an 830-bp fragment of the 
large tegument protein gene was used to confirm the PCR results by spot blot 
hybridisation.
RNA was treated with RNase-free DNase prior to reverse transcription-PCR (RT-PCR) 
with the MSRV specific primers for fragment B of the reverse transcriptase region of the 
pol gene as described by Perron et al. (1997). Only 5 pi of the DNase-treated RNA was 
used in the RT-PCR reaction using the Access RT-PCR system kit (Promega 
Corporation, Madison, Wisconsin, USA). A second round of amplification with the hemi- 
nested primer pair was performed and 2 pi RT-PCR product was carried over. The 
annealing temperature for PCR amplification during RT-PCR was 50°C. For the hemi- 
nested PCR 2.5 mM MgCh and 1 U Taq polymerase enzyme was used in the reaction 
mixture, at an annealing temperature of 55°C. The nested PCR product was 
electrophoresed in a 2% agarose gel and stained with ethidium bromide for 
documentation by UV-illumination. The PCR results were confirmed by overnight spot
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blot hybridisation at 50°C to the DIG-labelled plasmid containing the MSRV polymerase 
gene fragment (Perron et al., 1997).
Statistical analysis
Statistical analysis was performed by STATISTICA for Windows (StatSoft Inc. Tulsa OK, 
USA). Two-tailed Fisher exact test and the x2 calculation were applied as appropriate.
RESULTS
Table 1 shows the data obtained after screening for the presence of MS-associated 
retrovirus (MSRV) and two herpesviruses’ (HHV-6 and EBV) sequences in serum or 
peripheral blood (PBMC) of 49 MS patients, 33 close relatives and 39 unrelated control 
individuals. A significantly higher frequency of MSRV (P0.001) and HHV-6 sequences 
(P<0.04), and to a lesser extent of EBV (P=0.33) sequences, was observed in MS 
patients compared with unrelated controls. Overall, a statistically significant difference 
was observed between MS patients and unrelated controls (P0.001, 3 df, x2= 45.95). 
Interestingly, the viral sequences were detected at a similarly high frequency in the 
unaffected close relatives of the MS patients.
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Table 1: Comparison of the frequencies of viral sequences detected in MS patients, 
close family members and unrelated controls.
RR
n=37
MS patients 
n=49 (%) 
SP 
n=7
PP
n=5
Total
(%)
Close Family members 
n=20 (%)
Control group 
n=39 (%)
MSRV 25 (68) 4 (57 ) 5(100) 69 23 (70)* 0
EBV 17(46) 6(86) 2(40) 51 8(40 ) 15(38.5)
HHV-6 9(24) 1 (14) 1 (20) 22.5 2(10) 2 (5 )
None 5(13.5) 1 (14) 0 12 2(10) 23 (59)
Combinations
All three 2 (5 ) 1 (14) 0 6 0 0
MSRV/EBV 8 (22) 3(43) 2 (40 ) 27 6(30 ) 0
MSRV/HHV-6 4(11 ) 0 1 (20) 10 0 0
EBV/HHV-6 3 (8 ) 0 0 6 0 1 (3)
Total MS vs unrelated controls P< 0.001, df=3, %2= 45.95
*33 close family members were analysed for the presence of MSRV sequences.
MSRV, multiple sclerosis associated retrovirus; EBV, Epstein Barr virus; HHV-6, human herpes 6 virus 
RR, relapsing remitting; SP, secondary progressive; PP, primary progressive
Although the number of MS patients with a primary progressive disease course was 
small, it is noteworthy that all five individuals tested positive for MSRV sequences. Viral 
sequences were not confined to a specific genotype for the functional SLC11A1 gene 
promoter polymorphism studied earlier (Kotze et al., 2001) in a subset of the study 
population, but it is noteworthy that all the MS patients with the primary progressive 
disease course were homozygous for allele 3 of the SLC11A1 promoter polymorphism 
(table 2).
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Table 2: Presence of viral sequences for MSRV, EBV and HHV-6 in MS patients with 
different disease courses subdivided according to SLC11A1 genotype.
MS patients 
n=49
Virus SLC11A1 RR SP PP
Genotypes n=37 n=7 n=5
MSRV 2/2 1 1
2/3 11 1
3/3 8 1 5
3/5 5 1
EBV 2/2 1
2/3 9 2
3/3 7 2 2
3/5 1 1
HHV-6 2/2
2/3 4
3/3 5 1
3/5 1
Figure 1 illustrates the pedigree of one of the MS families included in this study. Co­
existence of MSRV sequences and alleles 3 and 5 of the SLC11A1 gene, which appears 
to predominate in South African MS patients (Kotze et al., 2001), was detected in the 
index patient. However, her aunt who was also diagnosed with definite MS, also has the 
SLC11A1 3/5 genotype but tested negative for all the virus sequences analysed. 
Furthermore, several of the family members without a diagnosis of MS tested positive for 
the virus sequences, SLC11A1 genotype 3/5, or both.
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Figure 1: Detection of sequences for MSRV, HHV-6 and EBV in an MS family 
genotyped for the 5'-(GT)n repeat polymorphism in the promoter region of the SLC11A1 
gene. The index case is indicated by an arrow.
DISCUSSION
In the present study significant differences between MS patients and unrelated control 
individuals were demonstrated with respect to the presence of MSRV (P0.001) and 
HHV-6 sequences (P<0.04), but not for EBV. However, no significant differences could 
be detected when the close family members of the MS patients were compared as 
unaffected controls. These findings suggest that the presence of viral sequences does 
not represent a primary causative agent for MS, but rather reflects the properties of 
viruses in the presence of relevant genetic and environmental factors involved in the 
pathogenesis of this complex disease. In one of the MS families studied (figure 1) the 
MSRV sequences were detected in only one of the two affected members, although 
both tested positive for SLC11A1 alleles 3 and 5 shown to be associated with MS in the 
South African population (Kotze et al., 2001). Familial aggregation in this family 
therefore seems to be limited largely to genetic factors, some of which may be shared 
by the unaffected mother and father of the index case. These findings highlight the
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complex nature of MS, where disease expression appears to involve more than one 
susceptibility gene (Vitale et al., 2002) in the presence of an appropriate environmental 
trigger(s). To our knowledge, this study represents the first analysis of MSRV sequences 
in unaffected family members of MS patients and therefore makes a valuable 
contribution to our current understanding of familial clustering in MS.
Evidence on potential mechanisms by which EBV can cause MS is limited. Failure to 
demonstrate EBV in MS plaques (Hilton et al., 1994; Morre et al., 2001) largely excludes 
the possibility that direct CNS infection is involved. It seems likely that the T-cell 
response to EBV infection could result in harmful cross-reaction with self-antigens. In a 
study performed by Knox et al. (2000) it was shown that blood samples of approximately 
50% (22/41) of patients with definite MS contain active HHV-6 infections, compared with 
none (0/61) of the normal controls. Although there was no significant difference between 
HHV-6 viraemia-positive and -negative MS patients with respect to type of disease 
(relapsing-remitting or progressive), patients with active HHV-6 viraemia were 
significantly younger and experienced a shorter duration of disease than in HHV-6 
viraemia-negative patients. In a recent study performed in Sardinia, Dolei et al. (2002) 
detected the MSRV in 12.8% of healthy blood donors versus 100% of patients with MS 
(P<0.000001). This finding remained significant when the study population was stratified 
in relation to other neurological conditions with respect to inflammatory disease, and it 
was concluded that the presence of MSRV in blood plasma may be related to the 
inflammatory nature of the disease, specifically those of both peripheral and CNS origin. 
Although the MSRV viral sequences were detected in other inflammatory CNS diseases 
like infectious encephalomyelitis and immune-mediated peripheral neuropathy, the 
occurrence was lower (Dolei et al., 2002). These findings were confirmed when no 
significance could be detected in comparison with other non-inflammatory neurological 
diseases. Differences in viral frequencies detected in MS cohorts in different studies 
may be related to population selection criteria applied or differences in experimental 
procedures.
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Although the number of patients with primary progressive MS included in this study is 
small, it is noteworthy that all the patients with this type of disease course tested positive 
for MSRV sequences. In addition, all of these individuals were homozygous for allele 3 
of the SLC11A1 promoter polymorphism, shown to be associated with an increased 
susceptibility to autoimmune diseases (Blackwell et al., 2000). These findings raise the 
possibility that viral gene expression remains active in patients with a progressive 
disease course while its activation from time to time in patients with relapsing-remitting 
MS may trigger the attacks. Further studies are warranted to determine whether this 
proposed effect in primary progressive MS is related to absence of allele 2 of the 
SLC11A1 5’-(GT)n repeat, which is protective against autoimmunity (Searle and 
Blackwell, 1999). Activation of a latent virus due to co-infection with another infectious 
agent remains a possibility in MS patients. Our data on co-existence of different virus 
sequences in MS subgroups does not provide sufficient evidence to explain such a role 
of MSRV in MS, although 61.8% of MS patients with MSRV expression harbored herpes 
viruses compared to 42.9% of all MS patients.
Although the exact role of infectious agents in the pathogenesis of MS has not been 
determined, it has been suggested that the presence of viral sequences may represent 
useful markers for diagnosis, prognosis and/or therapeutic monitoring of MS patients. 
From the results obtained in this study it seems justified to include detection of relevant 
viral sequences by PCR as a diagnostic tool, to complement the standard methods that 
are currently applied to make a diagnosis of MS. Although the presence of relevant viral 
sequences may be of prognostic value due to the association with disease activity 
(Wandinger et al., 2000), available antiviral drugs have little effect on MS (Cohen, 2000). 
It is therefore unlikely that a virus is the primary cause of MS and proof that this may be 
the case should come from the demonstration that a suitable vaccine prevents MS. 
Nevertheless, beta interferon, the neuroprotective drug currently used in the 
management of MS, has antiviral activity against HHV-6. Acquisition of one or more of 
the pathogens investigated in this study, presumably between early childhood and 
adolescence, may be responsible for triggering the autoimmune process underlying MS 
in genetically susceptible individuals, thereby contributing to the complex multi-step
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aetiology of MS. When the immune system is affected adversely by external exposures, 
commonly circulating virusses may be activated and under appropriate conditions may 
develop their full pathological potential. The likelihood that MSRV is produced 
endogenously and contribute to MS reactivation in the presence of predisposing 
conditions, can therefore not be excluded. Among the fundamental questions yet to be 
answered in understanding the pathophysiology of MS and other autoimmune diseases 
are (1) what initiates the inflammation and (2) what drives the inflammation in the target 
organ. Elucidation of the mechanisms responsible for the initiation of MS has obvious 
implications for future development of preventative therapy.
The data presented in this study support the hypothesis that virus infections may 
represent co-factors in the pathogenesis of some cases of MS and are associated with a 
more disabling disease course (Sotgiu et al., 2002). The detection of MSRV sequences 
in the majority of South African MS patients and their unaffected family members, whilst 
absent in unrelated control individuals, indicates that virus infections mostly affect the 
population risk and not familial risk. Other environmental factors such as iron, which 
interact with SLC11A1 known to regulate macrophage activation in infectious and 
autoimmune diseases (Blackwell et al., 2000), may contribute to environmental or 
familial risk, or both. Since the potential importance of this process has been clearly 
demonstrated in MS (Kotze et al., 2001; in press), further studies are warranted to 
elucidate the role of iron in the pathogenesis of MS. It is known that the continuous 
battle for iron between the host and invading pathogens may result in cytokine-mediated 
responses, which are involved in various infectious and autoimmune diseases.
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CHAPTER 2.4
Analysis of the 77C-G mutation in exon 4 of the PTPRC gene 
in multiple sclerosis
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Analysis of the 77C-G mutation in exon 4 of the PTPRC gene 
in multiple sclerosis
ABSTRACT
An analysis between multiple sclerosis (MS) and the gene encoding protein-tyrosine 
phosphatase, receptor-type C (CD45, PTPRC) known to be essential for activation of T 
and B cells, has recently been demonstrated in German and Italian MS patients, but not 
in patients from North America, Sweden or in a German follow-up study. In an attempt to 
clarify the role of the C to G transition at nucleotide position 77 in exon 4 of the PTPRC 
gene in MS, 124 unrelated South African and 353 German MS patients were subjected 
to mutation detection using polymerase chain reaction (PCR)-based methods. The exon 
4 mutation causing altered expression of CD45 isoforms on immune cells, was detected 
in one of the South African patients with MS, but was absent in her less severely 
affected sister who was also diagnosed with definite MS. This finding indicates that the 
mutation does not increase the risk of MS in South African patients, or that it is 
associated with earlier disability in this family. In the population-matched South African 
control group, none of the 85 subjects within the same age group tested positive for the 
mutation, while 5 of 52 elderly individuals above the age of 70 years (9.6%) carried the 
mutation (Fisher exact test, P=0.0085). This finding is similar to that described for the 
SLC11A1 gene in an earlier study and raises the possibility that the deleterious PTPRC 
mutation has been maintained in the population as a consequence of improved survival 
following infectious disease challenge. Although 13 of the 353 German MS patients (4%) 
were heterozygous for the PTPRC mutation compared with two of 140 (1.4%) control 
individuals from the same population, this difference was not statistically significant. The 
mutation was not confined to German patients with a specific disease course and no 
difference in mutation frequency could be detected between MS patients with different 
disease courses. The study included 134 patients with relapsing-remitting MS (38%), 74 
patients with secondary progressive MS (21%), 59 patients with primary progressive MS 
(17%) and 86 uncharacterised MS patients (24%). Our findings support the notion that 
genetic susceptibility factors of MS may vary between different population groups,
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although it seems more likely that the failure to confirm the association between MS and 
the PTPRC mutation in different study populations is due to the simplistic single-gene 
approach being used for data comparison in a complex disease.
INTRODUCTION
Multiple sclerosis (MS) is the most common demyelinating disorder of the central 
nervous system (CNS). Current knowledge suggests that MS is a multifactorial disease 
with a supposed autoimmune aetiology on the ground of genetic susceptibility and 
probably also disease-triggering infectious factors. No predictable pattern of inheritance 
is observed and clinical features of MS cannot yet be explained through an effect of a 
definable gene product or functional abnormalities (Chataway et al., 1998). The 
estimated familial occurrence in Caucasian MS populations is approximately 15%. The 
age-adjusted risk is higher for siblings (3%), parents (2%), and children (2%) than for 
second-and third-degree relatives (Compston and Coles, 2002).
Familial association in German MS patients has recently been reported by Jacobsen et 
al. (2000), as a consequence of a C-to-G transition at nucleotide position 77 in exon 4 of 
the protein-tyrosine phosphatase, receptor type C (PTPRC) gene. This alternatively 
spliced gene with 33 exons gives rise to 5 isoforms and encodes for a transmembrane 
protein tyrosine phosphatase that is expressed on all nucleated hematopoetic cells. In T- 
cells, its function is to prime the T-cell receptor that allows for its activation when 
interacting with an antigen presenting cell (Weiss and Littman, 1994). In humans a 
deficiency of this protein causes severe combined immunodeficiency disease (Kung et 
al., 2000). Interestingly, mice that contain an active form of this protein are hyper­
reactive to antigen and are prone to develop autoimmune disease (Majeti et al., 2000). 
The 77C-G mutation does not change the encoded amino acid, but prevents splicing of 
exon 4 pre-mRNA, an effect that could explain the reported association between MS 
and the PTPRC gene.
In a follow-up study of the 77C-G PTPRC mutation performed in a relatively large 
number of German MS patients and control individuals, no statistically significant
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difference in mutation frequency could be detected (Miterski et al., 2002). Likewise, no 
evidence of genetic association between MS and this mutation could be detected in 
American and Swedish MS patients (Barcellos et al., 2001; Vorechovsky et al., 2001). 
Ballerini et al. (2002) detected the 77C-G mutation in a small number of Italian MS 
patients but not in a matched group of healthy controls (Fisher exact test, P = 0.02). This 
finding suggests a role, in at least certain patient groups, for the PTPRC mutation in 
genetic susceptibility to MS.
Other mutations in the PTPRC gene may also be of relevance in MS, since Jacobsen et 
al. (2002) have also detected a novel C to A mutation in exon 4 at position 59 in one of 
22 MS families with aberrant CD45 expression, but without the 77C-G mutation. This 
mutation interferes with alternative splicing and with antibody binding to the CD45RA 
domain, similar to the effect previously described for the 77C-G mutation (Jacobsen et 
al., 2000).
In the present study DNA samples of 124 South African MS patients and 353 German 
MS patients were screened for the 77C-G mutation in exon 4 of the PTPRC gene, in 
order to determine possible allelic associations when compared with population- 
matched controls. The South African control group included 85 age-matched control 
individuals, as well as 52 elderly individuals above the age of 70 years, all from the 
Afrikaner population of European descent. The aged population provides a valuable 
source of material to determine whether certain deleterious sequence changes are 
retained in the population, possibly as a consequence of a selective advantage which 
may be related to the finding that certain alleles associated with autoimmunity protects 
against infectious diseases, while alleles associated with increased susceptibility to 
infection may conversely protect against autoimmune diseases. This phenomenon has 
been demonstrated earlier for the SLC11A1 gene shown to be associated with MS in the 
South African population (Kotze et al., 2001).
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SUBJECTS AND METHODS
Blood samples were obtained with written informed consent from 124 unrelated South 
African patients and 353 unrelated German patients diagnosed with definite MS, as well 
as relevant close family members. The patients were subdivided according to disease 
course: 134 relapsing remitting (RR), 74 secondary progressive (SP), 59 primary 
progressive (PP) and 86 uncharacterised MS patients. The South African patients were 
recruited mainly through the South African Multiple Sclerosis Society (Kotze et al., 
2001), while the German patients attended an outpatient clinic at the University Hospital 
Eppendorf in Hamburg, Germany. The diagnoses of MS in affected patients were based 
on clinical features (Poser et al., 1983), magnetic resonance imaging (MRI) and/or 
exclusion of other diseases known to manifest similarly. DNA samples of 85 healthy 
South African and 140 German individuals within the same age group as the MS 
patients, were included as controls. The 85 South African subjects included laboratory 
personnel, medical students and healthy blood donors within the same age- and 
population group. In addition, 52 elderly South Africans above the age of 70 years were 
recruited as population matched controls to study possible age effects. The Ethics 
Review committees of the Universities of Stellenbosch and Hamburg approved the 
study.
DNA analysis
Genomic DNA was extracted from peripheral blood, using a standard salting-out method 
(Miller et al., 1988) or commercial DNA extraction solution DNAzol (Invitrogen, UK), with 
minor modifications. PTPRC exon 4 specific primers (15pmol), 5’ -  atttattttgtccttctccca- 
3’ (forward) and 5’ -gttaacaacttttgtgtgcc -3 ’ (reverse) resulting in a 260-bp fragment 
following polymerase chain reaction (PCR)-amplification, were used in a 25 pi PCR 
reaction containing 50 ng of genomic DNA, 0.2 pM of each dGTP, dCTP, dATP and 
dTTP, 1.5 mM MgCl2, 10 mM Tris-HCI, 50 mM KCI and 0.5 U Taq DNA Polymerase 
(Roche - Diagnostics, Germany). PCR cycle conditions included an initial denaturing 
step at 95°C for 2 min, followed by 40 cycles at 95°C for 30 s, 60°C for 45 s, and 72°C 
for 30 s and performed in a 9700 Thermal Cycler (ABI, Foster City, CA, USA). PCR
Stellenbosch University http://scholar.sun.ac.za/
80
products were digested to completion with 5 U Mspl (Gibco, Gaithersburg, MD, USA) 
and subjected to polyacrylamide (PAA) gel electrophoresis (12% PAA, 3,4% C), stained 
with ethidium bromide and visualised by ultraviolet light.
Statistical analysis
Statistical analysis was performed by STATISTICA for Windows (StatSoft Inc. Tulsa, 
OK, USA). Two-tailed Fisher exact test was applied as appropriate. P-values <0.05 were 
regarded as statistically significant.
RESULTS AND DISCUSSION
Detection of mutation 77C-G in exon 4 of the PTPRC gene is shown in figure 1, 
following restriction enzyme analysis of PCR-amplified genomic DNA. In the mutation- 
negative control sample, fragments of 199-bp and 61-bp (lanes 1 and 3) are observed, 
while in the heterozygote the 199-bp fragment is cut into two additional fragments of 
115-bp and 84-bp in the mutant allele (lane 2). Only one of the 124 South African MS 
patients tested positive for the exon 4 mutation, compared to none of the 85 age- 
matched control individuals. The frequency of the 77G-C mutation was significantly 
increased in the elderly population compared with the younger controls (Fisher exact 
test, P=0.0085), since 5 of the 52 (9.6%) aged individuals were heterozygous for this 
mutation. The significant difference in mutation frequency observed between the two 
age groups in the South African control group raises the possibility that the deleterious 
PTPRC mutation has been maintained in the population as a consequence of improved 
survival following infectious disease challenge. A similar age effect has previously been 
demonstrated for the SLC11A1 gene shown to be associated with MS in the South 
African population (Kotze et al., 2001). Enrichment of the aged group for sequence 
changes associated with autoimmune disease suggests that these alleles may have 
some selective advantage. This may be of particular relevance in the South African 
context where epidemics of infectious diseases occurred in the past.
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199 bp
115 bp 
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Figure 1: Detection of mutation 77C-G using restriction enzyme analysis. DNA samples 
of mutation-negative control individuals (lanes 1 and 3) and a heterozygote for the 77C- 
G mutation (lane 2) is shown after digestion with Msp\ and electrophoresis on a 12% 
polyacrylamide gel.
Table 1 compares the mutation frequency for mutation 77C-G between different 
population groups analysed in this study and elsewhere. In the German study 
population, the G-allele at nucleotide position 77 of the PTPRC gene was present in 14 
out of 353 (4%) German and in 2 out of 140 (2%) control individuals. Contrary to the 
report of Jacobsen et al. (2000), who reported an association between this mutation and 
the development of MS in two independent German study cohorts, the role of the 77C-G 
mutation could not be demonstrated or confirmed in our German study cohort. In 
addition, no association could be detected when the mutation frequency in this patient 
group was compared to that reported for the German control samples studied by 
Miterski et al. (2002), which were recruited from the same geographical area.
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Table 1: Study comparisons of the 77C-G transition in the PTPRC gene.
Studv area Studv arouD Total 77C-G variant P-value
MS vs Controls
Marburg I (German) Multiple Sclerosis 219 14(6.4%) 0.00015
(Jacobsen et al., 2000)
Healthy donors 189 0
Marburg II (German) Multiple Sclerosis 108 7 (6.4%) 0.0058
(Jacobsen et al., 2000)
Healthy donors 114 0
American study Multiple Sclerosis 122 4 (3.2%) 0.55
(Jacobsen et al., 2000)
Healthy donors 244 9 (3.6%)
Hanover study (German) Multiple Sclerosis 76 5 (6.6%) 0.034
(Jacobsen et al., 2000)
Healthy donors 119 1 (0.8%)
Swedish study Multiple Sclerosis 630 19(3%) 0.62
(Vorechovsky et al., 2001)
Healthy donors 358 9 (3.2%)
American study Multiple Sclerosis 450 15(3.4%) 0.32
(Barcellos et al., 2001)
Healthy donors 253 6 (2.4%)
Bochum and Gottingen Multiple Sclerosis 454 7(1.6%) 0.15
(German) (Miterski et al.,
2002)
Hamburg (German) Healthy donors 347 10(2.8%)
Italian Multiple Sclerosis 194 5 (5.2%) 0.02
(Ballerini et al., 2002)
Healthy controls 222 0
Hamburg (German)* Multiple Sclerosis 353 13(4%) 0.15
Healthy controls 140 2(1.4%)
South Africa* Multiple Sclerosis 124 1 (0.8%) 0.59
Healthy controls 85 0
* this study; P-values <0.05 were regarded as statistically significant.
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Figure 2 shows the pedigree of the South African MS patient who tested positive for 
mutation 77C-G. This mutation was present in several unaffected family members, whilst 
absent in her sister who was also diagnosed with definite MS. The 54-year old South 
African MS patient with the PTPRC mutation has been diagnosed with RR MS at the 
age of 25 and has been wheelchair bound for the past 12 years. Her mutation-negative 
sister (aged 51 years) has been diagnosed with RR MS at the age of 32 years, and is 
still able to walk. This finding raises the possibility that the presence of the PTPRC 
mutation is associated with clinical severity of disease expression in this family.
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Figure 2: Pedigree of the South African family with two MS-affected sisters. Several 
family members tested positive for mutation 77C-G, including only one of the two sisters 
diagnosed with definite MS.
This study does not provide direct support for previous findings indicating an association 
between mutation 77C-G and MS susceptibility and points out that differences may 
occur between different population groups with regard to genetic susceptibility to MS. 
Meta analysis studies are warranted to clarify the role of the PTPRC mutation in MS.
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The selection of control populations are of mayor importance in case-control studies 
since population substructures may lead to false associations (Little et al., 2002). 
Although the role of mutation 77C-G in the South African and German populations 
studied is unclear, the mutation could possibly play a role in disease expression in 
combination with other environmental and genetic influences in certain families.
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CHAPTER 2.5
Co-existence of multiple sclerosis, 
haemochromatosis and variegate porphyria 
African family: C282Y homozygosity in two 
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hereditary 
in a South 
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Co-existence of multiple sclerosis, hereditary 
haemochromatosis and variegate porphyria in a South 
African family: C282Y homozygosity in two sisters with 
multiple sclerosis
ABSTRACT
Hereditary haemochromatosis (HH) is considered to be the most common (-1/250) 
autosomal recessive disorder in Caucasians of European descent, an ethnic group also 
known to have a genetic predisposition for multiple sclerosis (MS). Clinically manifested 
HH was, however, not recognised among 1700 MS patients previously studied in 
Canada. In order to determine whether this finding may be due to a linkage 
disequilibrium effect or gene-gene interaction, DNA samples of South African MS 
patients were screened for mutations H63D and C282Y in the HH gene. Identification of 
two copies of mutation C282Y in one of the index patients and her MS-affected sister, 
both without clinical manifestations of HH, provided evidence for possible gene-gene 
interaction. Haplotype studies performed in the MS family using microsatellite markers 
flanking the HH locus, demonstrated that the two MS patients were homozygous for 
specific alleles at marker loci D6S273 (A5, 135-bp), D6S105 (A5, 121-bp), D6S2239 
(A1, 105-bp) and heterozygous for marker D6S461 (A1, 253-bp; A9, 273-bp). This 
genotypic combination has not been observed in two healthy sisters, or their brother 
who tested positive for the R59W mutation causing variegate porphyria (VP). Evaluation 
of the study population for the specific alleles of each of the four markers identified in the 
C282Y homozygous MS patients, revealed a significantly increased frequency of the 
135-bp fragment of marker locus D6S273 in MS patients (51%) versus the control group 
(41%) (P0.05). This finding is in accordance with previous studies, which demonstrated 
significant linkage between MS and marker locus D6S273.
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INTRODUCTION
Iron is an essential nutritional element for normal functioning of a large number of 
enzymes involved in haem biosynthesis, neurotransmitter synthesis and degradation, 
myelin formation and oxidative phosphorylation (Aisen, 1994; Roskams and Connor; 
1994, Ponka, 1997). Changes in the normal distribution pattern of intracerebral iron, 
which may result in neurological dysfunction, have been described in both iron overload 
and iron deficiency (Larkin and Rao; 1990, Dexter et al., 1992; Jellinger and Kienzl, 
1993). The high demand of iron in the brain and the central nervous system (CNS) and 
their sensitivity to iron-induced peroxidative damage, suggests the need for stringent 
regulation of iron availability in these organs. Studies performed on brain tissue of 
patients with multiple sclerosis (MS) indicated disruption of the normal pattern of 
transferrin and ferritin binding (Hulet et al.,1999). These findings suggest that loss of 
ferritin binding may be involved in or is a consequence of demyelination associated with 
this chronic inflammatory disease of the CNS.
The functional linkage between immune function and iron absorption became evident 
with the identification of the major histocompatibility complex (MHC)-encoded HFE 
protein, underlying hereditary haemochromatosis (HH) (Feder et al., 1996, 1998). This 
finding provided evidence that MHC-encoded class I molecules might play a role in iron 
metabolism (Salter-Cid et al., 2000). Studies on iron accumulation in blood-brain barrier 
endothelial cells cultured under conditions mimicking iron status were in agreement with 
clinical studies in HH patients, suggesting that alterations in the peripheral iron status 
may affect the intracerebral iron concentration (van Gelder et al., 1998).
DNA screening of the South African population for two common haemochromatosis 
mutations, H63D and C282Y, has demonstrated that compound heterozygosity for these 
mutations or homozygosity for mutation C282Y is responsible for HH in more than 80% 
of affected Caucasian individuals (de Villiers et al., 1999a). These iron overload 
genotypes could also explain the porphyria phenotype in a relatively large proportion of 
patient referrals displaying symptoms suggestive of this group of haem biosynthesis
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disorders (de Villiers et al., 1999b), particularly patients who carry a definite diagnosis of 
sporadic porphyria cutanea tarda (PCT) (Hift et al., 1997). The carrier frequency of 
mutation C282Y was found to be 1 in 6 in the general Caucasian population of South 
Africa, with an estimated 1/115 homozygotes. Interestingly, a significantly lower carrier 
frequency (1 in 25) was detected in clinically affected index patients with the founder- 
related mutation R59W causing variegate porphyria (VP), implying that the HH gene 
may be a modifier locus for VP (de Villiers et al., 1999b). Although this autosomal 
dominant disease is extremely common in South Africa due to a founder effect (Dean, 
1972; Meissner et al., 1996; Warnich et al., 1996), approximately 80% of the estimated 
20 000 South African individuals with a defective VP gene remain clinically undetected 
(Day, 1986). The photosensitivity associated with VP may occur alone or in combination 
with acute symptoms such as abdominal pain, the passage of dark urine, and 
neuropsychiatric crises including bulbar paralysis, quadriplegia, motor neuropathy and 
weakness of the limbs. Some of the neurological manifestations of an acute porphyria 
are similar to that observed in MS (Rooney et al., 1999; Macy et al., 1991; Downey, 
1992; Pierach 1993). This is probably due to CNS dysfunction in both conditions, 
although the acute porphyrias also affect the peripheral nervous system (PNS). The 
overlap in clinical presentation of MS and VP is of particular relevance in South Africa 
where MS is considered to be rare (Dean, 1967), and many patients have been 
misdiagnosed with VP prior to the availability of a DNA diagnostic test (Kotze et al., 
1998).
HH is considered to be the most common autosomal recessive disease in Caucasians of 
Northern European decent, occurring in 1/200-300 individuals. It is therefore noteworthy 
that there were no subjects with clinically manifested HH recognised among 1700 
patients with multiple sclerosis (MS) encountered by Valberg et al. (1989), particularly 
since MS affects the same ethnic group. In this study DNA samples of 123 apparently 
unrelated South African patients diagnosed with MS were subjected to mutation 
screening of the HH gene, in order to determine whether this finding may be due to a 
linkage disequilibrium effect or gene-gene interaction.
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SUBJECTS AND METHODS 
Subjects
Relevant personal information was obtained from 281 South African patients diagnosed 
with MS, following distribution of a specifically designed questionnaire (published in the 
National Multiple Sclerosis Society newsletter) to support group meetings and 
physicians. Blood samples were obtained with informed consent from 142 apparently 
unrelated patients. The completed questionnaires were subsequently forwarded to the 
patients' neurologists for verification of the MS diagnoses. Non-Caucasian South African 
MS patients, recent immigrants and patients without a definite diagnosis of MS were 
excluded from this study, leaving 123 index cases for DNA analysis. The diagnosis of 
MS in these patients was based on standard criteria, including selected clinical features 
(Poser et al., 1983), lumbar puncture, MRI and/or exclusion of other diseases known to 
manifest similarly. The study protocol was approved by the Ethics Review committee of 
the University of Stellenbosch.
DNA screening for the common HH mutation C282Y revealed homozygosity in one of 
the index patients, a 51-year old female. She developed gait difficulty with leg weakness 
in 1982 following pregnancy, numbness of the trunk and a burning sensation in her legs 
in 1984, when the MS diagnosis was made at the age of 32 years. In 1985 she had an 
episode of probable optic neuritis. Her hands have become progressively weaker and 
her face intermittently numb. Nerve conduction studies were normal. The disease 
course was relapsing-remitting initially, subsequently becoming chronic progressive. 
She has a history of iron deficiency anaemia evidenced by low transferrin saturation 
concentration during child-bearing years and received treatment (dietary iron 
supplementation) for this condition in the past. The family history revealed that four 
subjects in the first generation of her family (figure 1) were previously diagnosed with 
variegate porphyria (VP) based on routine biochemical analysis of blood, stool and urine 
specimens. Follow-up clinical investigations performed for this study at Tygerberg 
Hospital include MRI of the brain (Dr J Carr), liver function tests and radioisotope studies 
of the liver (Dr S Schmit), using standard techniques.
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Haematological, Biochemical and Immunological analysis
Full blood counts, performed on a Technicon H2 blood cell counter and serum iron, 
transferrin and ferritin concentrations, were determined in a routine diagnostic 
laboratory. Serum iron was measured with a Beckman CX7 autoanalyser, and 
transferrin with a Beckman Array Nephelometer. Transferrin saturation was 
subsequently calculated. Transferrin receptor concentration was measured using an 
enzyme immunoassay (Human Transferrin Receptors Kit, Ramco Laboratories). Liver 
biopsies could not be performed, but since unusually high CD4:CD8 ratios were shown 
to precede the development of severe iron overload (Porto et al., 1997), T-cell 
phenotyping was carried out in four subjects to serve as a marker for iron loading. This 
procedure was performed after red cell lysis of whole blood analysed by flow cytometry 
(Becton Dickinson).
Mutation screening
Genomic DNA was isolated from whole blood using a standard salting-out method 
(Miller et al., 1988). Screening for the HH gene mutations H63D and C282Y was 
performed by restriction enzyme analysis of polymerase chain reaction (PCR)-amplified 
DNA using Mbo\ and Rsa\, respectively (Feder et al., 1996; Roberts et al., 1997). 
Possible mistyping of C282Y homozygosity was excluded by MseI restriction enzyme 
analysis as previously described (de Villiers and Kotze, 1999). R59W mutation 
screening of the protoporphyrinogen oxidase (PPOX) gene underlying VP was 
performed according to Warnich et al. (1996).
Haplotype analysis
Microsatellite genotyping was performed on ABI310 and ABI3100 automated 
sequencers using fluorosceinated oligonucleotide primers corresponding to loci D6S273, 
D6S105, D6S2239 and D6S461 (table 1). Primer sequences are available at 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=UniSts. The map order 
is cen - D6S273 - D6S105 - (HFE gene) - D6S2239 -  D6S461. D6S2239 is the closest 
marker (<20 kb) to the HFE gene (Feder et al., 1996). Previous genome screens have
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indicated that D6S273 (Haines et al., 1996) and D6S461 (Ebers et al., 1996) may be 
closely linked to putative MS loci. Between markers D6S273 and D6S461 there are 295 
genes.
Table 1: Numbering of alleles for marker loci D6S237, D6S105, D6S2239 and D6S461 
according to increasing repeat length.
Marker loci and PCR fragment sizes in base pairs
D6S273 D6S105 D6S2239 D6S461
A1 127 113 105 253
A2 129 115 107 255
A3 131 117 109 261
A4 133 119 111 263
A5 135 121 113 265
A6 137 123 267
A7 139 125 269
A8 127 271
A9 129 273
A10 131 275
A11 133
A12 135
A13 139
Statistical analysis
Statistical analysis was performed by STATISTICA for Windows (StatSoft Inc. Tulsa, 
OK, USA). Two-tailed Fisher exact test and the x2 calculation were applied as 
appropriate. P-values <0.05 were regarded as statistically significant.
RESULTS
DNA screening for HH mutations H63D and C282Y in 118 (of the available 123) 
apparently unrelated South African MS patients revealed homozygosity for mutation 
C282Y in one individual. None of the MS patients were compound heterozygotes for 
mutations C282Y and H63D, whilst the carrier frequencies of both mutations were 
approximately 15% in the MS patient group (table 2). Although a statistically significant
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difference was not observed between MS patients and controls, the frequency of the 
generally more common H63D mutation was lower in the patient group.
Table 2: Comparison of genotype distribution and allele frequencies of HH mutations 
C282Y and H63D in MS patients and controls drawn from the same population.
Controls* (n=102) Patients (n=118)
Genotype
C282Y++/H63D— 2 (2%) 1 (0.9%)
C282Y+-/H63D+- 1(1%) 1 (0.9%)
C282Y+-/H63D— 14(13.7%) 21 (18%)
C282Y—/H63D++ 0 1 (0.9%)
C282Y—/H63D+- 24 (23.5%) 16 (14%)
C282Y—/H63D— 61 (59.8%) 78 (66%)
Allele
282-G (normal) 0.91 0.90
282-A (mutant) 0.09 0.10
Carrier frequency 16.9% 18%
63-C (normal) 0.88 0.92
63-G (mutant) 0.12 0.08
Carrier frequency 21.1% 14.7%
*de Villiers et al., 1999a
The pedigree of the MS patient found to be homozygous for mutation C282Y is shown in 
figure 1. Mutation analysis in 17 additional family members of the index case (II-5) 
revealed the same genotype in her sister (II-4), who also has a diagnosis of MS. None of 
the other first- or second-generation relatives of these sibs were homozygous for the 
C282Y mutation, while this genotype was detected in all three children (aged 16-23 
years) of the index patient. Since patient II-5 reported a family history of VP, mutation 
screening of the PPOX gene was also performed. As shown in figure 1, the founder- 
related mutation R59W was detected in five family members, of whom four are sibs in 
the first generation.
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Figure 1: Pedigree of the index MS patient (II-5) found to be homozygous for mutation 
C282Y. Subjects diagnosed with multiple sclerosis (MS) are indicated in dark-shaded 
symbols, while those with mutation R59W causing variegate porphyria (VP) are 
indicated in light-shaded symbols. The genotypes for mutation C282Y in the HH gene, 
and microsatellite marker loci D6S273, D6S105, D6S2239 and D6S461 (in alleles, table 
1), are indicated below the pedigree symbols. Only those family members of whom DNA 
samples were available are numbered.
Haplotype studies performed in the MS family using microsatellite markers flanking the 
HH locus, demonstrated that the two MS patients were homozygous for specific alleles 
at marker loci D6S273 (A5, 135-bp), D6S105 (A5, 121-bp), D6S2239 (A1, 105-bp) and 
heterozygous for marker D6S461 (A1, 253-bp; A9, 273-bp). This genotypic combination 
has not been observed in their unaffected brother and two sisters (figure 1).
Evaluation of the study population for the specific alleles of each of the four markers 
identified in the C282Y homozygous MS patients (highlighted in table 3), indicated that 
the 135-bp fragment of marker locus D6S273 previously shown to be linked to MS 
(Haines et al., 1996), predominates in the South African MS patients (51%) versus the
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control group (41%) (P<0.05, 1 df, a,2=3.9). No significant difference was however 
detected when the allelic distribution was considered for all the alleles combined 
(P>0.05, 6 d f , /2=12.58). Detection of the 135-bp allele in 31/50 chromosomes of C282Y 
homozygotes previously diagnosed with HH (data not shown), suggests that a gene 
involved in MS susceptibility may occur on the chromosome carrying the C282Y 
mutation in some cases.
Table 3: Genotype distribution and allele frequencies of microsatellite marker loci 
D6S105, D6S273, D6S2239 and D6S461 on chromosome 6. The alleles detected in the
Marker Fragment size 
(base pairs)
Allele MS Control
D6S273 127 A1 5 (2.6%) 12(7%)
129 A2 7 (3.6% 16 (9.4)%
131 A3 29(15%) 24 (14%)
133 A4 27(14%) 29 (17%)
135 A5 101 (52%) 70 (41%)
137 A6 14 (7%) 8 (4.7%)
139 A7 13(6.6%) 11 (6.5%)
Total 196 170
D6S105 113 A1 2 (0.8%) 0
115 A2 4(1.7%) 7 (4.9%)
117 A3 1 (0.8%) 1 (0.7%)
119 A4 4(1.6%) 5 (3.5%)
121 A5 66 (27%) 30 (21%)
123 A6 27(11%) 25(17.6%)
125 A7 62 (25.6%) 31 (21.8%)
127 A8 35 (14%) 18 (12.7%)
129 A9 24(10%) 14 (9.9%)
131 A10 6 (2.5%) 4 (2.8%)
133 A11 9 (3.7%) 7 (4.9%)
135 A12 1 (0.4%) 0
139 A13 1 (0.4%) 0
Total 242 142
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Table 3 continue
D6S2239 105 A1 81 (33%) 50 (33.3%)
107 A2 54 (22%) 36 (24%)
109 A3 107 (43.5) 61 (40.7%)
111 A4 4(1.6%) 3 (2%)
Total 246 150
D6S461 253 A1 5 (2.4%) 5 (4.7%)
261 A3 7 (3.3%) 2(1.9%)
263 A4 29 (14%) 6 (5.7%)
265 A5 64 (30.7%) 28 (26.4%)
267 A6 57 (27.4% 28 (26.4%)
269 A7 9 (4.3%) 4 (3.8%)
271 A8 20 (9.6%) 18(17%)
273 A9 16(7.6%) 15(14.2%)
275 A10 1 (0.5%) 0
Total 208 106
Determination of iron parameters (after an overnight fasting period) revealed abnormal 
profiles in several family members of index patient 11-5 (table 4). Elevated transferrin 
saturation and ferritin levels, correlating with homozygosity for mutation C282Y, were 
evident in the two sisters (11-4, 11-5) diagnosed with MS, as well as the oldest son (111-4) 
of the index case. Although the raised ferritin levels detected in family members 1-3, 1-4 
(and elevated transferrin saturation), 11-2, 11-7 and 11-8 may partly be due to 
heterozygosity for mutation C282Y, the reason for the high serum levels of this acute 
phase protein in two mutation-negative male spouses (11-1, II-6) is unknown. The 
youngest son (III-5) of the index patient, who inherited two copies of mutation C282Y 
from his parents, presented with a normal iron profile, except for slightly raised 
transferrin saturation (53.5%). The daughter (III-3) demonstrated an increased serum 
transferrin receptor concentration suggestive of mild iron deficiency, which appears to 
contradict the detected homozygosity for mutation C282Y.
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Table 4: Iron profiles determined in members of the index family following an overnight fasting period
No Gender Age
(yrs)
Haemoglobin 
F: (11.5-16.5 g/dl) 
M: (12.5-17.5 g/dl)
Serum Iron* 
(6-32 nmol/l) 
(7-35 nmol/l)
Transferrin 
(1.8-3.8 g/l) 
(1.8-3.8 g/l)
Tr Saturation
(15-50%)
(20-50%)
Ferritin 
(20-150 fxg/l) 
(20-228 ng/l)
T r Receptor 
(42-69 ng/ml) 
(42-69 ng/ml)
1-1 M 88 n.d. 12.6 2.7 20.2 38 92.9
I-2 F 81 13.3 14 3.1 20.2 69 89.6
I-3 F 73 14.3 18.2 2.31 34.7 248 64
I-4 M 71 14.6 25.3 1.89 58.9 285 41.1
11-1 M 53 17.9 30.1 2.9 45.2 559 57.9
II-2 F 52 14.1 17.2 2.4 31 253 49.8
II-3 M 52 n.d. 19.6 2.8 31 228 70.4
II-4 F 50 n.d. 27.8 1.7 65, 96 280 34.1
II-5* F 48 13.3 32.8 1.7 77 347, 238 18.1,25.8
II-6 M 49 15.8 16.8 2.53 29.2 312 60.19
II-7 F 45 15.4 18.4 2.5 32.9 251 71.1
II-8 M 40 17.2 23.2 2.3 43.6 416 47.1
111-1 M 21 16.9 20.7 2.7 34.4 210 53.6
III-2 F 28 n.d. 13 2.6 22.4 125 78.7
III-3 F 23 15.5 20.7 2.4 38 76 77.1
III-4 M 22 15.8 39.8 1.5 92,100 480 37.5
III-5 M 16 15.9 26.5 2.2 53.5 43 49
III-6 F 19 14.0 13.3 2.71 21.6 9 n.d.
‘ Index case. Her most recent ferritin level was 175 |jg/l without treatment for iron overload.
Numbering refers to the Pedigree in figure 1
Reference ranges for females and males are given in parenthesis for each parameter. Levels outside these values are highlighted. 
F, female; M, male; n.d., not determined; Tr, transferrin
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Since evidence has previously been provided that heterozygosity for mutation C282Y 
may protect against iron deficiency (Datz et al., 1998), we compared the iron profiles of 
17 of the female MS patients of European descent found to be heterozygous for this 
mutation against reference values (table 5). In five of these patients (29.4%) low serum 
ferritin levels, a reliable parameter of iron depletion, were measured. Two patients 
(11.8%) presented with raised serum ferritin concentrations.
Table 5: Non-fasting iron profiles of 17 female MS patients heterozygous for mutation 
C282Y in the HH gene._________________________________________________________
No. Age
(yrs)
Haemoglobin 
(11.5-16.5 g/dl)
Serum Iron 
(6-32 nmol/l)
T ransferrin 
(1.8-3.8 g/l)
Tr Saturation 
(15-50%)
Ferritin 
(20-150 jag/l)
13 41 12.5 14.2 2.8 20 19.4
28 39 n.d. 6.7 4.0 7 6.2
41 26 14.5 29.3 2.8 42 54.4
45 22 13.5 20.9 3.7 23 105.8
52 61 13.8 21.2 3.5 24 10.8
54 46 n.d. 9.0 2.4 16.5 25.1
58 36 15.0 14.2 2.4 24 88.8
60 61 12.5 15.8 2.5 25 17.6
66 24 13.3 28.7 3.0 38 90.2
77 69 n.d. 17.0 2.4 28 114.9
84 35 12.5 4.2 2.7 6.9 7.0
99 52 n.d. 3.1 1.8 7.4 99
108 53 14.7 19.4 1.9 41 210.7#
111 64 14.9 24.7 3.2 33.9 70.7
112 41 n.d. 20.9 3.2 29.3 40.3
117 43 16.0 n.d. n.d. n.d. 39
120
____ X -- .
43 12.8 14.9 2.0 32.9 203.4#
"Elevated serum ferritin concentration; Levels suggestive of iron deficiency are highlighted
Since the two sisters previously diagnosed with MS were both shown to be homozygous 
for the C282Y mutation, follow-up neurological examinations were requested. The 
results were consistent with the diagnosis of MS in both cases. The index patient (II-5) 
had mild bilateral optic atrophy, saccadic smooth pursuit, spastic legs, generalised 
hyperreflexia, diminished light touch over the legs and trunk with a level corresponding 
to the T4 dermatome, slowed fine finger movements and slowed rapid alternating 
movements. Magnetic resonance imaging (MRI) results were consistent with a diagnosis
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of definite MS in this patient and no iron deposition could be detected in the brain (figure
HL
03-JAN-1951 
15:06
24 FEB-1998 
IMAGE 25 
STUDY 4
MF 1.12
tirlml5 180 
*R 2200
TR 7500.0
IE 150.0/1
TA *03:37
AC I  2
CITY PARK MR1 CENTRE 
mCNETat IMPACT 
H-SP VB31B 
+ : F A L
C 357
Figure 2: T-2 weighted magnetic resonance imaging lesions in the brain of patient 11-5. 
(Image reproduced with permission of Dr R Hewlett, Christiaan Barnard Memorial 
Hospital, Cape Town).
The sister of the index patient (11-4) was also diagnosed with definite MS with a relapsing 
remitting course. She is a 54-year old female whose neurological symptoms (onset age 
25) include gait difficulty and numbness of both legs. She has been wheelchair bound 
for the past 12 years. On examination she had presented with bilateral optic atrophy, 
impaired smooth pursuit, saccadic dysmetria, mild dysarthria, bilateral internuclear 
ophthalmoplegia, spastic quadriparesis (with lower limbs markedly more affected than 
the upper), extensor plantars bilaterally, diminished light touch (more severe over her
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left side and including the left side of her face), mildly impaired joint position sense in the 
toes and markedly impaired co-ordination in all limbs. Nerve conduction studies were 
normal. During recent years her condition remained relatively static without active 
exacerbations.
The abnormal iron profiles of subjects II-4 and II-5 did not result in organ damage. None 
of the patients are known to have any dietary idiosyncrasies, they never donated blood 
and both underwent hysterectomies approximately 5 years ago. In the index case this 
procedure was performed due to the presence of myomas, and in her (wheelchair- 
bound) sister mostly for practical purposes. Liver-function tests and radio-isotope 
studies were normal in both cases (data not shownj. Liver biopsies were not performed 
to further assess the likelihood of iron accumulation caused by elevated serum iron 
levels, since this could not be justified ethically, but T-cell phenotyping largely excluded 
the possibility of iron overload due to the presence of mutation C282Y. The CD4:CD8 
ratios (Porto et al., 1997) were very low (<3) in the index patient (1.26). Low CD4:CD8 
ratios were also detected in her oldest son (III-4, 1.33) and youngest sister (II-7, 1.67). 
Comprehensive phenotyping of the immune system in mice revealed no detectable 
anomalies within various T cell compartments, suggesting that high CD4:CD8 ratios 
observed in HH patients may, at least in part, be secondary manifestations of severe 
iron overload.
DISCUSSION
Multiple lines of evidence, ranging from population to family studies, support the role of 
genetic factors in susceptibility to MS (Ebers et al., 1995; Haines 1996; Haines et al., 
1998; Rothwell and Charlton, 1998). The importance of human leukocyte antigen (HLA) 
status in MS susceptibility and the complex nature of the disease have recently been 
demonstrated in a large North American pedigree with an apparent autosomal dominant 
inheritance pattern, since co-inheritance of two loci were shown to be involved in 
disease susceptibility (Vitale et al., 2002). Risch (1987) reported that the effect of a HLA-
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linked locus accounts for only a 2.5-fold increased risk of MS to sibs over the population 
prevalence, compared to the observed value of 20.
In this study we investigated the possible significance of the HH genotype (C282Y, 22), 
co-existing with the MS phenotype, in a family with VP. The aetiology of MS is poorly 
understood, and therefore co-existence of genetic disorders in large families may 
contribute to the elucidation of the disease mechanism(s). In contrast to the high 
prevalence of VP in South Africa, MS is considered to be uncommon among white 
Afrikaners (Dean, 1967, 1972; Kotze et al., 1998). Some striking similarities between MS 
and the acute porphyrias (Macy et al., 1991; Downey, 1992) raised the possibility that 
several South African patients with partial expression of MS, or a proposed new subtype 
of the disease (Rooney et al., 1999), have been misdiagnosed with VP prior to the 
availability of a DNA test for this condition. Since the opposite can probably also occur, 
we first excluded VP in the index case and her sister by screening for mutation R59W 
segregating in this family. The absence of peripheral nervous system involvement, an 
important feature distinguishing MS from the acute porphyrias (both affect the central 
nervous system) and many other diseases that may masquerade as MS (Natowicz and 
Bejjani, 1994), supported a diagnosis of MS in the family. Mutation R59W causing VP 
was detected in five family members of index patient II-5, facilitating accurate diagnosis 
of this condition which is dependent on interaction with other genetic and/or 
environmental factors (Kaupinnen and Mustajoki, 1992) for clinical expression.
A strong correlation has been demonstrated between signal intensity and iron 
concentration in the liver (Thomsen et al., 1992), and these data suggest that increased 
iron accumulation may occur in the brain of patients with HH. Neurological features 
associated with HH are rare, but psychomotor retardation, lethargy, fatigue, confusion, 
hearing loss and polyneuropathy have previously been described (Milder et al., 1980). 
Nielsen et al. (1995) furthermore reported a patient with HH who presented with 
dementia, dysarthria, a slowly progressive gait disturbance, muscle weakness, rigidity, 
tremor and ataxia, which were most likely caused by excessive iron accumulation in the
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basal ganglia and cerebellum. The likelihood that (some of) the neurological features of 
subject II-5 are caused by deposition of iron in the brain was excluded by MRI.
Measurement of serum iron levels in the 17 female MS patients found to be 
heterozygous for mutation C282Y revealed diverse iron profiles that may represent a 
non-specific response due to inflammation associated with the disease process. 
Detection of values suggestive of iron deficiency in 6 cases (35%) nevertheless appears 
to contradict the notion that a single copy of this gene may protect women against iron 
deficiency (Datz et al., 1998). This may, however, apply to the general population but 
not to subjects with an inherited defect to absorb or transport iron normally. Earlier, 
Valberg et al. (1989) reported partial expression of the HH gene in heterozygotes from a 
control group, although a similar trend was not apparent in MS patients analysed by the 
authors. These findings provide additional support for the notion that intermittent iron 
deficiency may be related to the disease phenotype in a subgroup of MS patients 
(Rooney et al., 1998).
Homozygosity for mutation C282Y in index patient II-5 was unexpected, since she 
received treatment for iron deficiency (low transferrin saturation) in the past. Liver 
function tests and radio-isotope studies did not reveal any abnormalities in this patient, 
or her C282Y homozygous sister who also has MS, despite the fact that biochemical 
testing demonstrated elevated transferrin saturation and ferritin levels indicative of HH in 
both subjects. It is noteworthy that the MS phenotype of the sister, who did not 
supplement her diet with iron on a regular basis in the past, is more severe than that of 
the index case. Symptoms of HH presenting in 40-60% of HH homozygotes usually 
become apparent between the ages of 40 and 50 years, unless certain protective 
measures are taken, such as regular donation of blood, or if other gene(s) modulate the 
expression of disease-related mutations. In a report on a family displaying non­
expressing C282Y homozygosity (Rhodes et al., 1997), variability in disease expression 
induced by gender did not account for differences in expression, as evidenced by the 
development of overt disease in two C282Y homozygous sisters (aged 50 and 53 years) 
who had both borne children. It is also interesting to note that the HLA-identical sister of
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the non-expressing C282Y homozygote studied by Rhodes et al. (1997) had a history of 
iron deficiency, probably as a consequence of coeliac disease, despite the fact that her 
transferrin saturation (57/76%) and ferritin levels (157/258 pg/l) were elevated. This 
finding suggests that serum concentrations of certain iron parameters are not always a 
true reflection of iron status in tissue and that iron deficiency is possible in C282Y 
homozygotes, as previously reported in patient II-5. Consequently, we speculate that 
such a situation is unlikely to be ascribed solely to environmental factors, and that 
unknown gene mutations predisposing individuals to an unusual form of (intermittent) 
iron deficiency may be involved.
This study demonstrated that homozygosity for mutation C282Y (genetic HH), in 
association with the 135-bp allelic fragment of marker locus D6S273 shown to be 
associated with a putative MS susceptibility gene (Haines et al., 1996), has not caused 
organ damage in the two sisters with MS. This finding, together with the data reported 
by Valberg et al. (1989), implies that MS and clinically manifested HH may be mutually 
exclusive as a consequence of gene-gene interaction, and provides further support for a 
role of iron metabolism in the aetiology of MS.
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CHAPTER 3 
CONCLUSIONS
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CONCLUSIONS
Defining the cause of MS represents a major challenge because little is certain about 
the pathogenesis of this neurological disease. The varied clinical picture of MS raises 
the possibility that it is not a well-defined aetiology, but consists of genetically different 
subtypes in addition to subtypes with no genetic contribution (phenocopies) (Rasmussen 
and Clausen, 2000). It seems highly likely that different genes and environmental factors 
are involved in the induction and progression of MS and that external factors may affect 
the population risk and genetic susceptibility the familial risk. The proposed role of iron 
in the aetiology of MS may explain this complexity.
Analysis of the iron transporter gene encoding the natural resistance-associated 
macrophage protein (NRAMP1), recently renamed the solute carrier family 11 (proton- 
coupled divalent ion transporters) member 1 (SLC11A1), represented the first attempt to 
investigate the likelihood that iron dysregulation in association with infectious and/or 
autoimmune disease susceptibility, may underlie the MS phenotype in a subgroup of 
patients. The Z-DNA forming repeat polymorphism in the promoter region of the gene 
was significantly associated with MS (P<0.01) in the genetically homogeneous Afrikaner 
population of South Africa. The potential significance of the Afrikaner population as a 
valuable source of material for identification of genes involved in complex conditions 
was highlighted by failure to confirm this association in the German and French 
populations using a case-control study and transmission linkage disequilibrium 
approach, respectively. Although this could mean that the SLC11A1 gene is not involved 
in MS, it seems more likely that the unique genetic background of the Afrikaner 
population enabled the detection of a true association due to the fact that an expected 
limited number of disease-associated genes/mutations were probably introduced from 
Europe. Such a phenomenon would exclude some of the possible confounding factors 
complicating the identification of genes involved in complex diseases. Support for this 
conclusion was obtained by the detection of significant differences in genotype 
distribution among German MS patients with different disease courses. Due to the
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important role of SLC11A1 in iron regulation, it would appear that genotyping of the 5’- 
(GT) repeat polymorphism, together with determination of iron concentration in CNS and 
serum (LeVine et al., 1999; Zeman et al., 2000) may represent important determinants 
of disease course in MS patients.
Based on the above findings, the Afrikaner population was furthermore exploited to 
confirm or exclude an association reported between MS and a deleterious point 
mutation (77C->G) in the gene encoding protein-tyrosine phosphatase, receptor-type C 
(PTPRC). This gene plays an essential role in the activation of T and B cells and was 
found to be associated with MS in the German population, although most of the follow- 
up studies performed to date failed to confirm this association. Analysis of the Afrikaner 
population did not indicate a causative role for the PTPRC gene in MS, a finding 
substantiated by the fact that the German study population included in our study also 
failed to demonstrate an association between MS and mutation 77C->G in the PTPRC 
gene. However, it seems likely that this mutation may contribute to disease expression, 
since in one of the South African families with two MS affected sibs, the most severely 
affected sister was heterozygous for the 77C->G mutation. The PTPRC mutation may 
therefore be of significance in disease prognosis, mainly within the family context.
To investigate a viral influence in the apparent multi-step aetiology of MS, serum and 
peripheral blood mononuclear cells (PBMCs) of MS patients, close relatives and 
unrelated controls were screened for the presence of MS-associated retrovirus (MSRV) 
and two herpes virus (HHV-6 and EBV) sequences. Comparison of frequencies of viral 
sequences among these groups was performed within the context of the genetic 
background, in an attempt to provide a better definition of MS subgroups and disease 
expression within specific families. Detection of virus sequences at similar frequencies in 
South African MS patients and their unaffected close relatives (MSRV), whilst absent or 
present at a significant lower frequency (HHV-6) in the serum of unrelated healthy 
control individuals, indicated that virus infections affect the population risk but not the 
familial risk in MS.
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Viral sequences were not confined to a specific genotype for the functional SLC11A1 
gene promoter polymorphism, which excluded the possibility that the presence of allele 
2 is related to the detection of viral sequences in MS patients. This allele increases the 
risk of infection but conversely protects against autoimmune disease (Searle and 
Blackwell, 1998). Although the number of South African MS patients with a primary 
progressive disease course was relatively small, all of them tested positive for MSRV 
sequences and were homozygous for allele 3 of the SLC11A1 promoter polymorphism, 
which is associated with increased susceptibility to autoimmune diseases. These 
findings raise the possibility that the viral sequences remain active in patients with a 
progressive disease course, particularly in the absence of an autoimmune-protective 
allele 2, while activation of viral sequences in patients with relapsing-remitting MS may 
trigger the attacks from time to time.
Finally, some evidence for gene-gene interaction suggesting genetic influences involving 
iron metabolism, was provided in MS patients with a genetic predisposition for iron 
overload. In two MS-affected sisters with hereditary haemochromatosis (HH) due to the 
presence of two copies of mutation C282Y, no organ damage could be detected despite 
elevated serum iron parameters and the fact that both patients underwent 
hysterectomies several years ago. Since co-existence of genetic disorders in large 
families may contribute to the elucidation of disease mechanism(s) in complex 
conditions such as MS where the aetiology remains poorly understood, further 
investigation is warranted to define the genetic factors underlying the clinical phenotype 
in this family. It seems likely that a MS susceptibility locus could in some cases occur on 
the same chromosome carrying the C282Y mutation, thereby explaining the relatively 
high incidence of MS in Northern European populations where HH is prevalent.
The multidisciplinary approach used in this study towards elucidation of the aetiology of 
MS, has led to a stepwise accumulation of scientific information, which resulted in a new 
perspective on the disease process. It became clear that a simplistic single-gene search 
for MS susceptibility genes is not likely to provide the information required for 
development of a comprehensive diagnostic assay for this complex condition, due to
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inconsistent findings in different population groups and even in subgroups of the same 
population. Based on the data provided in this study, it seems possible that a combined 
screening strategy including analysis of viral sequences and certain population-specific 
genetic factors might, together with current methods of diagnosing MS, provide a more 
conclusive means of early disease diagnosis or to distinguish between MS subtypes that 
may be of prognostic value. The ultimate approach would, however, be to utilise new 
sophisticated technology allowing simultaneous analysis of expression patterns of 
thousands of genes in a single experiment for individual profiling aimed at disease 
diagnosis and treatment.
Future Prospects
The human genome project has provided a tool for large-scale high-throughput analysis 
of differential gene expression, allowing progress in functional interpretation of genomic 
information. Of these methods, DNA microarrays and quantitative real-time PCR have 
been utilised most extensively. Microarrays are sophisticated detection systems that can 
read and quantify minute amounts of cDNA to simultaneously detect over- and under­
expression of multiple genes. The results obtained could then be validated by gene 
expression studies utilising the sensitive real-time PCR technology. Only recently these 
methods of mutation detection and gene expression became available to the research 
community and will dramatically affect the direction and way research will be performed 
in future. Developing countries still lack the financial ability to develop facilities where 
such high-throughput genotyping and transcriptional profiling can be performed, but 
collaboration with international centres of excellence could alleviate this problem.
In a collaborative study with researchers at the University of Oxford, the monocyte 
chemotactic protein-3 {MCP-3) gene was shown to be significantly over-expressed in 
the samples of South African MS patients, but not in the control samples (M.G. Zaahl et 
al., unpublished data -  abstract submitted for congress presentation). This finding 
prompted us to analyse a CA/GT repeat in the promoter-enhancer region of MCP-3 to 
further investigate the role of this gene in MS. A significant difference was observed in
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allelic distribution between 117 South African MS patients and 73 population-matched 
controls (P<0.05, 3 df, x2=9.14). Sequencing of the coding region of three MS patients 
showing over-expression of MCP-3 did not reveal any sequence changes, which is in 
accordance with involvement of the promoter region in MCP-3 over-expression. This 
does not necessarily point towards a genetic susceptible gene for MS, but possibly more 
towards the mechanism related to the formation of lesions in the brains of MS patients.
Since the data obtained with microarray analysis confirm previous findings of a 
significant association between MS and the MCP-3 gene (Nelissen et al., 2002), a 
comprehensive genetic test based on these and related findings will be developed for 
diagnostic purposes. This represents a classical example of how new technology can 
fast forward genetic research by defining disease-related mechanisms in a single 
experiment.
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